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• Aim: Identification of new effective and selective trypanocidal agents. Materials & methods: Twelve novel 
acetohydroxamic acid derivatives based on 2-alkyl-2-aryl-2,6-diketopiperazine scaffolds have been synthesized 
and evaluated in vitro for their growth inhibitory activity against bloodstream form T. brucei. Results: All the 
analogues were remarkably potent inhibitors, with low micromolar to submicromolar activities. Structure-
activity relationship studies demonstrated that the presence of an alkyl substituent at the N(4)-position of the 
2,6-diketopiperazine ring portion was, in general, beneficial to trypanocidal activity in this series. Conclusions: 
The highest activity resulted from the introduction of a methyl, n-propyl or n-butyl substituent to the N(4)-
position of the parent compound. Importantly, the most potent analogues were found to be highly selective 
against T. brucei with respect to mammalian cells.    
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Human African Trypanosomiasis (HAT) or sleeping sickness is amongst the most serious neglected tropical 
diseases and is caused by infection with parasitic protozoa of the Trypanosoma brucei subspp [1,2]. HAT 
constitutes a major public health risk within 36 sub-Saharan Africa countries due to its epidemic character [2,3]. 
It is estimated that 70 million people are at risk, and that around 3000 new infections occur every year in the 
endemic disease foci [2]. Current treatments for HAT have been based on old drugs including, suramin, 
pentamidine, melarsoprol and eflornithine, with an eflornithine-nifurtimox combination introduced in 2009 
[1,2,4] although oral fexinidazole has shown considerable promise in clinical trial and has recently been 
recommended for use ([5] Ku Mesu, V.K.B.K., Kalonji, W.M., Bardonneau, C., Mordt, O.V., Blesson, S. (2018) Oral 
fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, 
randomised, non-inferiority trial. Lancet 391, 144-154. [6] European Medicines Agency recommends 
fexinidazole, the first all-oral treatment for sleeping sickness. https://www.dndi.org/2018/media-centre/press-
releases/). These drugs are often associated with severe toxic side effects, poor efficacy, and problematic 
administration. Additionally, the HAT drugs are expensive, and their usage requires adequate medical care, 
which is not readily available in the most affected regions of sub-Saharan Africa [2,4]. All the above issues with 
the existing HAT drugs emphasize an imperative need for research and development of new efficient, safe, and 
affordable antitrypanosomal therapeutics. 
In 1999, it was discovered that bloodstream form T. brucei are sensitive in vitro to the anti-influenza A drugs 
amantadine I and rimantadine II. Rimantadine was also found to be toxic to the trypanosomatid parasites T. 
cruzi and Leishmania major.5 Two years later, it was reported that a series of aminoadamantane and 
aminoalkylcyclohexane derivatives are effective growth inhibitors of T. brucei in vitro and in vivo, and that 
inhibition was correlated with the hydrophobicity of the compounds. Some of these derivatives (III-IV, Figure 1) 
showed submicromolar trypanocidal activities in vitro; in particular the adamantane analogue III (IC50=0.33 μΜ) 
gave 400- and 21-fold increases in antitrypanosome potency compared to amantadine and rimantadine, 
respectively.6 In our earlier works we communicated the trypanocidal properties of some nitrogen-containing 
adamantane derivatives (amines or not).7,8 Among them, compounds V-VII (Figure 1) possessed considerable 
activities in vitro against T. brucei. Oxazolone V8 was the most active inhibitor of the parasite growth, exhibiting 
a potency that was 3-fold higher than rimantadine and at least 45-fold greater than amantadine, while the 
trypanocidal activity of spiro piperidine VI7 was found to be 1.5 times more than rimantadine, and at least 25 
times greater than amantadine. The spiro barbituric analogue VII7 displayed more potent inhibition (7-fold) than 
that of amantadine, although it was ~3-fold less effective than rimantadine. 
In pursuit of a better antitrypanosome potency we explored the trypanocidal properties of the structurally 
related spiro 2,6-diketopiperazine derivatives VIIIa and VIIIb. Unfortunately, these compounds were only 
marginally active against T. brucei parasite. Yet, compounds VIIIa and VIIIb as well as other lipophilic spiro 
carbocyclic 2,6-DKPs represent useful scaffolds that can be transformed into potent trypanocidal agents, with 
single nanomolar to submicromolar activities, by introducing an acetohydroxamic acid moiety to their imidic 
nitrogen [5,6]. Thus, we produced a series of lipophilic, constrained spiro carbocyclic 2,6-diketopiperazine-1-
acetohydroxamic acid derivatives (Fig. 1., 1a-g, 2, 3, 4a-d, 4f, 5a, 5b, 5d) that displayed single nanomolar to 
submicromolar activities. [5,6] SAR studies showed the indispensability of the hydroxamic unit (CONHOH) for 
the trypanocidal activity in this class of compound [5]. Thus, we presumed that these hydroxamates act by 
inhibiting a decisive parasite metalloenzyme due to the metal ion coordinating properties exerted by the 
hydroxamic acid group in the catalytic site. We have also confirmed that incorporating a benzyl rather than an 
aliphatic substituent into the methylene carbon next to the basic nitrogen of the spiro carbocyclic 2,6-DKP 
portion leads to analogues (Fig. 1., 1f, 1g, 2, 3 and 4f) with the higher trypanocidal activity. 
 
In order to identify the structural features of the 2,6-DKP-based acetohydroxamic acids required for potent 
trypanocidal activity, we modified the spiro carbocyclic 2,6-DKP core structure by changing the spiro-linked 
carbocycle component for an alkyl and an aryl substituent. In this report, we present the design and synthesis 
of a new series of acetohydroxamic acid analogues (Fig. 1. 6-17) as T. brucei growth inhibitors based on 
conformationally non-constrained 3-alkyl-3-aryl-2,6-DKP scaffolds. Within this series, we studied the 
trypanocidal potency of compounds in relation to: (a) the length of the C-3 n-alkyl substituent (compounds 6-
8), (b) the para-substitution on the aromatic ring with fluorine atom or nitro group (compounds 9 and 10), and 
(c) the alkyl substitution at the N(4)-position of the 2,6-DKP ring (compounds 11-17). The antitrypanosomal 
properties of these novel compounds were assessed against T. brucei bloodstream form parasites in vitro.   
 
Figure 1. Structures of amantadine I, rimantadine II, lipophilic adamantane derivatives III-VII, 2,6-DKPs VIIIa and 
VIIIb, spiro carbocyclic 2,6-diketopiperazine-1-acetohydroxamic acid derivatives 1a-g, 2, 3, 4a-d, 4f, 5a, 5b, 5d 
reported previously [X-X], and structures of the new acetohydroxamic acid analogues 6-17 based on 3-alkyl-3-
aryl-2,6-diketopiperazine scaffolds.  
 
2. Results and Discussion 
2.1. Chemistry 
 
Compounds 6-17 were synthesized following similar procedures to those reported in our previous publications 
(Schemes 1 and 2) [5-7]. As shown in Scheme 1, the Strecker reaction of the ketones 18-22 with ethyl glycinate 
hydrochloride and sodium cyanide, and subsequent acidic hydration (H2SO4 97%) of the unstable α-aminonitrile 
intermediates (not shown) provided the respective amide-ester derivatives 23-27, which served as key 
compounds for further elaboration. Treatment of compounds 23-27 with potassium bis(trimethylsilyl)amide in 
THF gave, after an SN2 reaction of the intermediate potassium imidate salts with benzyl or 4-methoxybenzyl 
bromoacetate in DMF, the corresponding 2,6-DKP-1-acetic acid benzyl ester derivatives 28-32. An analogous 
base-catalyzed intramolecular cyclization of the amide-ester derivatives 23-27 using potassium 
bis(trimethylsilyl)amide (1eq), followed by the addition of TFA (1eq) led to their respective 2,6-DKPs 42-46. 
Reductive methylation on the basic nitrogen atom of the 2,6-DKPs 42-46 with CH2O/NaCNBH3 in MeOH or 
MeOH-THF 1:1 gave the corresponding methyl substituted analogues 47-51. The latter compounds, upon 
reaction with benzyl or 4-methoxybenzyl bromoacetate in the presence of sodium hydride in DMF, were 
converted to the N-methylated 2,6-DKP-1-acetic acid benzylester derivatives 52-56. Catalytic hydrogenolysis 
(H2/10% Pd-C) of the benzyl esters 28-31 and 52-55 occurred cleanly to afford the carboxylic acids 33-36 and 
57-60, which underwent efficient CDI coupling reactions with O-benzylhydroxylamine to give the O-benzyl 
hydroxamates 37-40 and 61-64, respectively. The desired hydroxamic acids 6-9 and 11-14 were available via 
catalytic hydrogenolysis (H2/10% Pd-C) of the benzyl-protected hydroxamates 37-40 and 61-64, respectively. 
Additionally, treatment of the 4-methoxybenzyl esters 32 and 56 with TFA, followed by CDI-catalyzed coupling 
reactions of the respective carboxylic acid intermediates (not shown) with O-(4-methoxybenzyl)hydroxylamine 
gave the corresponding O-(4-methoxybenzyl) hydroxamates 41 and 65. The removal of the 4-methoxybenzyl 
protecting group of 41 and 65 was achieved by exposure to TFA in the presence of triethylsilane in CH2Cl2 
affording the targeted nitro-substituted hydroxamic acid analogues 10 and 15, respectively. 
 
 
Scheme 1. Reagents and conditions: (a) NaCΝ, H2NCH2CO2Et.HCl, DMSO/H2O 29:1 (v/v), rt, 48h; (b) (i) H2SO4 
97%, CH2Cl2, rt, 24h; (ii) ice and then aq. NH3 26% to pH 7-8, 20-55% yields over two steps; (c) (i) (Me3Si)2NK (1 
eq), THF, 0-5°C then rt, 2h, argon; (ii) BrCH2CO2CH2C6H5 or BrCH2CO2CH2C6H5OCH3-4 only for 32, DMF, rt, 48h, 
argon, 73-91%; (d) Η2/Pd-C, EtOH or EtOH-AcOEt 3:1 for 35, 50 psi, rt, 3h, 96- >99% for 33-36, 57-60, 75-94% for 
6-9, 11-14; (e) (i) CDI, THF for 37-40, 61-63 or THF-DMF 4:1 for 64, 28 °C for 37-39, 61-63 or 55 °C for 40, 64, 1h, 
argon; (ii) C6H5CH2ONH2.HCl, Et3N, 28 °C, 24h and then 45 °C, 1h, argon, for 37-39, 61-63 or 55 °C, 25h, argon, 
for 40, 64, 61-76%; (f) (i) CF3CO2H, CH2Cl2, rt, 90 min; (ii) Et3N, CDI, THF, 28 °C, 1h, argon; (iii) 4-
CH3OC6H4CH2ONH2, 28 °C, 18h, then 55 °C, 7h, argon, 48% and 43% yields over two steps for 41 (from 32) and 
65 (from 56), respectively; (g) CF3CO2H, CH2Cl2, rt, 10 min, then Et3SiH, rt, 45 min, 63% for 10 (as hydrochloride) 
from 41, 70% for 15 from 65; (h) as (c) (i), then CF3CO2H (1 eq) 91-96%; (i)(i) aq CH2O 37%, MeOH or MeOH-THF 
1:1 for 51, rt, 3h, then NaCNBH3, rt, 4h at pH 6-7 (maintaining by adding AcOH); (ii) NaOH 1N and Na2CO3 to pH 
8, 74-88%; (j) NaH, DMF, rt, 1h or 10 min for 56, argon and then as (c) (ii) using BrCH2CO2CH2C6H5 or 
BrCH2CO2CH2C6H5OCH3-4 only for 56, 71-87%. 
Scheme 2 shows the synthesis of the hydroxamic acid analogues 16 and 17, bearing a n-propyl (16) or n-butyl 
(17) aliphatic substituent at the basic nitrogen atom of the 2,6-DKP scaffold. Treatment of acetophenone 18 
with n-propylamine or n-butylamine hydrochloride and sodium cyanide, followed by acid-catalyzed hydration 
of the unstable α-aminonitrile intermediates (not shown) gave the respective amino amides 66 and 67. These 
 
compounds were then reacted with ethyl bromoacetate in the presence of sodium bicarbonate in DMF to 
provide the corresponding amide-ester derivatives 68 and 69. Employing a four step reaction sequence similar 
to that described above for the preparation of the hydroxamic acid congeners 6-9, the amide-ester derivatives 
68 and 69 were converted to the hydroxamic acid analogues 16 and 17, respectively. The 1H and 13C NMR spectra 
for the acetohydroxamic acid analogues described in this report (compounds 6-17) are consistent with E/Z 
conformational behavior of these molecules in solution. The assignment of the E and Z isomers was based on 
our E/Z conformational isomerism study reported previously [8]. 
 
Scheme 2. Reagents and conditions: (a) NaCΝ, CH3(CH2)2NH2.HCl for 66 ή CH3(CH2)3NH2.HCl for 67, DMSO/H2O 
29:1, rt, 48h; (b) (i) H2SO4 97%, CH2Cl2, rt, 24h, (ii) ice and then aq. NH3 26% to pH 7-8, 45% (66) and 47% (67) 
yields over two steps; (c) BrCH2CO2Et, ΝaHCO3, DMF, 40-43 °C, 6d, 57% for 68, 47% for 69; (d) (i) (Me3Si)2NK, 
THF, 0-5 °C and then rt, 2h, argon; (ii) BrCH2CO2CH2C6H5, DMF, rt, 48h, argon, 89% for 70, 81% for 71; (e) Η2/Pd-
C, EtOH, 50 psi, rt, 3h, 93% for 72, 98% for 73; (f) (i) CDI, THF, 28 °C, 1h, argon, (ii) C6H5CH2ONH2.HCl, Et3N, 28 
°C, 24h and then 45 °C, 1h, argon, 65% for 74 and 75; (g) (i) as (e), (ii) HCl in Et2O, 70% for 16, 68% for 17. 
2.2. Biological Activity 
The newly synthesized hydroxamic acid derivatives 6-17 were tested against bloodstream form T. brucei in vitro. 
The IC50 and IC90 values for each compound are summarized in Table 1. As shown, 10 out of the 12 tested 
compounds had IC50s values in the low to submicromolar range against T. brucei (compounds 6-8 and 11-17) in 
the free base and hydrochloride forms. The cytotoxicities of the most active compounds against mammalian 
cells were also determined using the rat skeletal myoblast L6 cells (Table 1.), with most displaying very favorable 
selective indices. 
The initial compound prepared in this 3-alkyl-3-aryl-2,6-DKP-1-acetohydroxamic acid series, 6, exhibited 
appreciable trypanocidal activity both as free base and hydrochloride salt, with IC50s of 6.97 and 6.61 μΜ, 
respectively. Replacement of the C-3 methyl substituent in the 2,6-DKP sacaffold of 6 with n-propyl or n-butyl 
side chains led to the respective more lipophilic C-3 alkyl substituted analogues 7 and 8. These compounds 
displayed activities that were comparable to that of 6; the C-3 propyl analogue 7 (IC50=7.25 μΜ or 6.93 μΜ as 
hydrochloride) was almost equipotent to the parent structure 6, whereas the C-3 butyl counterpart 8 (IC50=1.72 
or 1.85 μΜ as hydrochloride) had approximately 4-fold higher activity than 6 and 7. However, it is apparent that 
lengthening of the C-3 alkyl chain in compounds 7 and 6 by one and three methylene carbons, respectively, 
boosted potency towards T. brucei to a noteworthy level (8 vs 6 and 7). These results demonstrate that the 
lipophilicity and / or possible steric effects of the C-3 n-alkyl chain influence the trypanocidal activity in this 
subset of compounds. 
 
Substitution at para-position of the phenyl moiety in the parent structure 6 by either a lipophilic or hydrophilic 
electron-withdrawing substituent, such as a fluorine atom or a nitro group was slightly detrimental to activity. 
The p-fluoro substituted analogue 9 was 2.7 and 2 times less potent than the parent 6, when these compounds 
were tested in the free base and hydrochloride salt forms, respectively, while the p-nitro congener 10 proved 
1.8-fold less potent than 6 when comparing the IC50s of their corresponding hydrochloride salts. On the other 
hand, the para-fluoro analogue 9 and the para-nitro congener 10 displayed almost equal activity in the form of 
their corresponding hydrochloride salts (9, IC50=12.9 μΜ; 10, IC50=11.7 μΜ). These findings imply that the 
observed activity-decrease in compounds 9 and 10 was largely unaffected by the lipophilic or hydrophilic 
properties, as well as the size of the electron-withdrawing para-substituent. 
The addition of a methyl substituent to the N(4)-position of the 2,6-DKP ring [N(4)-methylation] in the parent 
compounds 6, 7, 9 and 10 appeared to have a favorable effect on the trypanocidal activity and resulted in a 1.5-
12-fold increase in potency for the respective N-methylated analogues 11, 12, 14 and 15. The greatest 
improvement in potency was observed with the N-methyl analogue 11 (IC50=0.59 μΜ or 0.55 μΜ as 
hydrochloride), which showed a significantly increased trypanocidal activity (12-fold), relative to the 
unsubstituted parent 6. The N-methyl derivatives 12 and 15 also gave quite better potencies compared to the 
corresponding parent structures 7 and 10; the C-3 propylated free base 12 and its hydrochloride (12.HCl) had 
4.1 and 5.5 times greater trypanocidal activity than 7 and 7.HCl, respectively, whereas compound 15 in the form 
of its hydrochloride salt (15.HCl) was 9-fold more potent than the hydrochloride salt of 10. However, a slight 
decrease (1.5-fold) in activity was detected in the case of the C-3 butylated N-methyl counterpart 13 upon N(4)-
methylation of the corresponding parent molecule 8. It is interesting that the effect of the N(4)-methylation on 
the trypanocidal activity within the N-methyl derivatives series 11-13 seemed to be inversely related to the 
length of the alkyl side chain at the 3-position of the 2,6-DKP ring, as observed by comparing the analogue pairs 
11/6, 12/7 and 13/8. While the N(4)-methylation of the parent structure 6 led to a significant increase in potency 
(12-fold) for the C-3 methyl-substituted N-methyl analogue 11, it was less beneficial (approximately 4 to 5-fold 
increase) and slightly detrimental (1.5-fold decrease) in the cases of the C-3 propyl- and C-3 butyl-substituted 
N-methyl counterparts 12 and 13, respectively. These results might be due to the steric interference in the active 
site. 
The marked difference in increasing potency between the N-methylated derivative 11 and the corresponding 
NH-analogue 6 prompted the introduction of a longer hydrophobic alkyl substituent such as n-propyl or n-butyl 
groups to the N(4)-position of the 2,6-DKP scaffold in parent 6. These N(4)-alkyl substitutions led to significantly 
effective derivatives which inhibited T. brucei growth at submicromolar concentrations. The N-propyl derivative 
16 (IC50=0.47 μΜ) and the n-butyl counterpart 17 (IC50=0.63 μΜ) in the form of their hydrochloride salts proved 
14- and 10.5-fold more potent than the hydrochloride salt of the N-alkyl free congener 6, respectively. However, 
both N-alkylated compounds 16 and 17 exhibited trypanocidal potencies similar (in the order of 0.5 μΜ) to the 
potency of the N-methyl derivative 11. These results indicate that the length and lipophilicity of the N(4)-alkyl 
substituent were not important for potent activity within the group of the acetohydroxamic acid analogues 11, 
16, and 17, in which the C-3 alkyl substituent of the 2,6-DKP scaffold is identical. 
Notably, the most active compounds in this series (8, 11-13 and 15-17) displayed remarkably low cytotoxicity 
against mammalian cells (with the exception of compounds 8 and 13), having selectivity indices ranging from 
180 (12) to 1180 (11). In particular, the acetohydroxamic acid derivatives 11, 16 and 17, which had the highest 
activity against T. brucei (IC50=0.55, 0.47 and 0.63 μΜ, respectively), displayed the best selectivity with respect 
to  
L6 cells. 
Table 1. Activity of acetohydroxamic acid analogues 6-17 tested against cultured bloodstream-form T. brucei 
(pH=7.4) and cytotoxicity of the most active compounds against cultured rat skeletal myoblast L6 cells. 
 Activity  
 
Cpds T. brucei Cytotoxicity L6 cells 













ND (39±2) (21) 
9 19.1±2.5 
(12.9±0.6) 
32.9±1.2 (20.3±0.5) ND - 

































16d (0.47±0.02) (1.13±0.15) (354±37) (750) 
17d (0.63±0.08) (1.39±0.03) (186±32) (295) 
aConcentrations required to inhibit growth of T. brucei by 50% and 90%, respectively. 
bIC50 and IC90 data are the mean of triplicate experiments ± SEM. 
cCytotoxicity was determined by establishing the concentration required to inhibit growth of cultured L6 cells 
by 50%  (IC50). Data are the mean of triplicate experiments ± SEM.  
dSelectivity indices were calculated as the ratio of the IC50 for L6 cells and T. brucei. 
eData in brackets refer to the respective hydrochloride. ND: Not determined. 
 
3. Conclusion  
We have developed a novel series of acetohydroxamic acid derivatives that inhibit the bloodstream form T. 
brucei parasite growth with low micromolar or submicromolar IC50 values. These inhibitors were derived from 
3-alkyl-3-aryl-2,6-DKP scaffolds by incorporating an acetohydroxamic acid moiety as metal chelating group in 
their imidic nitrogen atom. Nevertheless, the new class of compounds were found to be less potent than the 
spiro carbocyclic 2,6-DKP congeners 1-5.x,x The observed decrease in antitrypanosome potency of the new 
compounds 6-17 might be ascribe to their lower lipophilicity, and unfavorable stereoelectronic factors. Within 
the N(4)-alkyl free analogues 6-8,  a C-3 propyl instead of C-3 methyl substitution resulted in an almost 
equivalent antitrypanosome effect (compare 7 to 6), whereas a significant enhancement in potency was 
observed upon C-3 butyl substitution (8 vs 6). Substitution at the para-position of the phenyl moiety in the 
parent 6 by a fluorine atom or nitro group resulted in a slight reduction of activity (compound 9 and 10). 
 
Introduction of a methyl substituent to the NH-position of the 2,6-DKP ring [N(4)-methylation] in the 
unsubstituted compounds 6-10 has, in general, a positive influence on the potency against T. brucei, as 
represented by the N(4)-methyl analogues 11, 12, 14 and 15. Among the latter compounds, the N(4)-methyl 
derivative 11 was the most potent against trypanosomes, with  a submicromolar IC50 value (0.55 μΜ). However, 
a similar submicromolar T. brucei inhibitory effect (approximately 0.5 μΜ) was obtained, when the N(4)-methyl 
group in 11 was replaced by a propyl or butyl n-alkyl chain, as  in the respective N(4)-substituted counterparts 
16 and 17 (Table 1.). Importantly, the most potent compounds of this series were found to be highly selective 
in inhibiting T. brucei growth over mammalian cells. Currently, the target of these acetohydroxamic acid 
derivatives in trypanosomes is unknown. Their submolar potency against T. brucei and their relative lack of 
toxicity to mammalian cells suggests that general metal chelation activity is unlikely. Rather, we would favor a 
more specific mode of action, analogous to inhibitors of histone deacetylase that have anti-cancer potential, 
where the mechanism involves binding of the hydroxamate to zinc ions in the catalytic site of the enzyme (Finnin 
MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a 
histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188–193.). Identification of 





4. Materials & Methods 
4.1 Chemistry 
4.1.1. General 
Melting points were determined using a Büchi capillary apparatus and are uncorrected. 1H and 13C NMR spectra 
were obtained on Bruker MSL 400 (400 MHz 1H, 100 MHz 13C), Bruker AVANCE III 600 (600 MHz 1H, 150 MHz 
13C) and Bruker AVANCE 200 (50 MHz 13C) spectrometers, using CDCl3 or DMSO-d6 as solvent. Chemical shifts 
are reported in δ(ppm) with tetramethylsilane or solvent (DMSO-d6) as internal standard. Splitting patterns are 
designated as s, singlet; d, doublet; dd, doublet of doublets; t, triplet; td, triplet of doublets; q, quartet; qd, 
quartet of doublets; m, multiplet; dm, doublet of multiplets; br, broad; v br, very broad; sym, symmetrical. The 
spectra were recorded at 293 K (20 °C) unless otherwise specified. Carbon multiplicities were established by 
DEPT experiments. 2D NMR experiments (HMQC and COSY) were performed for the elucidation of the structures 
of the newly synthesized compounds. Low-resolution mass spectra were recorded on either an API 2000 LC-
MS/MS or Thermo-Finnigan AQA model LC-MS system, using positive electrospray ionization mode or Thermo 
Electron Corporation DSQ mass spectrometer in chemical ionization (CI) in positive ion mode with methane as 
CI reagent gas or in electron impact (EI). High-resolution mass spectra (HRMS) were determined on a hybrid 
LTQ-Orbitrap Discovery mass spectrometer under electrospray ionization (ESI) or atmospheric pressure 
chemical ionization (APCI) in positive ion mode. Analytical thin-layer chromatography (TLC) was conducted on 
precoated Merck silica gel 60 F254 plates (layer thickness 0.2 mm) with the spots visualized by iodine vapors 
and/or UV light. Column chromatography purification was carried out on silica gel 60 (70-230 and 230-400 mesh 
ASTM). Elemental analyses (C, H, N) were performed by the Service Central de Microanalyse at CNRS (France) 
or Department of Microanalysis of NCSR “Democritos” (Greece), and were within ±0.4% of the calculated values, 
except where noted (compounds 10 and 33.HCl). The purities of the tested compounds were determined by 
analytical HPLC and elemental analysis. The obtained results correspond to >95% purity. Analytical HPLC was 
performed on a Thermo Finnigan HPLC system (Thermo Finnigan, San Jose, USA) consisting of a SpectraSystem 
P4000 pump, a SpectraSystem  100 degasser, a SpectraSystem  AS3000 autosampler, and a SpectraSystem  
UV2000 PDA detector, controlled by a SpectraSystem  controller. ChromQuest 4.1 software was used for the 
management of the data. For the HPLC-DAD, a Supelco Analytical Discovery HS C18 (250 mm x 4.6 mm, 5.0 μm) 
 
column was used and the injection volume was 10 μL. The mobile phase consisted of H2O and 1% acetic acid 
(solvent A) and acetonitrile (solvent B), and solvent gradient of A/B was 95/5 to 0/100. The analyses were 
performed at r.t. with a constant flow rate of 1 mL/min using a gradient elution of 0-50 min. The commercial 
reagents were purchased from Alfa Aesar, Sigma-Aldrich and Merck, and were used without further purification 
except for the benzyl bromoacetate and ethyl bromoacetate. These reagents were purified by distillation prior 
to use. 4-Methoxybenzyl bromoacetate used, was prepared according to our previously published experimental 
protocol [6]. O-(4-Methoxybenzyl)hydroxylamine was synthesized according to the literature reported method 
[9]. Organic solvents used were in the highest purity, and when necessary, were dried by the standard methods. 
Yields refer to chromatographically pure materials. 
4.1.2. N-[(1-Aminocarbonyl-1-phenyl)ethyl]glycine ethyl ester 23 
To a stirred suspension of sodium cyanide (1.37 g, 27.9 mmol) and ethyl glycinate hydrochloride (3.9 g, 27.9 
mmol) in 18 mL of DMSO-H2O 9:1 (v/v), a solution of acetophenone 18 (3.2 g, 26.6 mmol) in DMSO (36 mL) was 
added in one portion. The reaction flask was sealed, and the mixture was allowed to react for 48 h at room 
temperature with stirring. After this time, the mixture was poured into ice-water (200 mL) and extracted with 
Et2O (4 × 60 mL). The combined organic extracts were washed with water (2 × 50 mL), dried, and the solvent 
was evaporated in vacuo at room temperature to avoid thermal decomposition of the reaction product (α-
aminonitrile). The obtained oily residue was dissolved in CH2Cl2 (140 mL), cooled in an ice-water bath, and 
treated dropwise with H2SO4 97% (32 mL) under vigorous stirring. The resulting mixture was stirred at room 
temperature for 24 h, and carefully poured into crashed ice (170 g). To this two-phase mixture, aqueous NH3 
26% was added dropwise to pH=7-8 with stirring under cooling (ice-water). The phases were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 × 100 mL). The combined organic fractions were washed once with 
water (100 mL) and once with brine (100 mL), dried, and evaporated in vacuo. The remaining crude oil was 
purified by flash column chromatography with AcOEt-Et2O 1:1, as eluent, to afford the title compound 23 as a 
white crystalline solid (1.35 g, 20% overall yield): mp 88-90 °C (AcOEt/Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) 
δ 1.15 (t, 3H, J=7.1 Hz, CO2CH2CH3), 1.62 (s, 3H, CH3), 2.26 (s, 1H, NHCH2CO2CH2CH3), 3.11-3.26 (~q, 2H, J=17.3 
Hz, NHCH2CO2CH2CH3), 4.0-4.14 (q, 2H, J=7.1 Hz, CO2CH2CH3), 6.43 (br s, 1H, CONHH), 6.94 (br s, 1H, CONHH), 
7.15-7.51 (m, 5H, aromatic H); 13C NMR (100 MHz, CDCl3) δ 14.0 (CO2CH2CH3), 22.6 (CH3), 45.4 
(NHCH2CO2CH2CH3), 60.9 (CO2CH2CH3), 64.5 (C6H5(CH3)CNH), 126.2, 127.5, 128.4 (2,3,4,5,6-aromatic C), 141.6 
(1-aromatic C), 172.1 (CO2CH2CH3), 177.5 (CONH2). Anal. Calcd for C13H18N2O3: C, 62.38; H, 7.25; N, 11.19; Found: 
C, 62.24; H, 7.10; N, 11.24. 
4.1.3. N-[(1-Aminocarbonyl-1-phenyl)butyl]glycine ethyl ester 24 
Prepared from butyrophenone 19 (3.95 g, 26.6 mmol) according to the method described for compound 23. The 
crude oil was purified by column chromatography on silica gel with AcOEt-n-hexane 1:1, as eluent, to afford the 
title compound 24 as a colorless viscous oil (1.5 g, 20% overall yield); 1H NMR (400 MHz, CDCl3) δ 0.87 (t, 3H, 
J=7.3 Hz, CH3(CH2)2), 1.06-1.21 (complex m, 5H, CH3CH2CH2, CO2CH2CH3), 1.94-2.18 (dm, 2H, CH3CH2CH2), 2.19-
2.40 (br s, 1H, NHCH2CO2CH2CH3), 3.06-3.18 (q, 2H, J=17.0 Hz, NHCH2CO2CH2CH3), 4.05-4.12 (q, 2H, J=7.1 Hz, 
CO2CH2CH3), 6.03 (s, 1H, CONHH), 6.93 (s, 1H, CONHH), 7.15-7.30 (complex m, 3H, aromatic H), 7.39-7.46 
(complex m, 2H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.2 (CH3(CH2)2), 14.4 (CO2CH2CH3), 16.7 (CH3CH2CH2), 
35.8 (CH3CH2CH2), 45.1 (NHCH2CO2CH2CH3), 61.1 (CO2CH2CH3), 67.4 (C6H5(n-C3H7)CNH), 126.5, 127.5, 128.6 
(2,3,4,5,6-aromatic C), 141.0 (1-aromatic C), 172.1 (CO2CH2CH3), 176.7 (CONH2); HRMS (ESI): [M+H]+ calcd for 
C15H22N2O3, 279.1709, found 279.1705. 
4.1.4. N-[(1-Aminocarbonyl-1-phenyl)pentyl]glycine ethyl ester 25 
Prepared from valerophenone 20 (4.32 g, 26.6 mmol) according to the method described for compound 23. The 
crude oil was purified by flash column chromatography eluting with AcOEt-n-hexane 1:2 to 3:1 to afford the title 
compound 25 as a colorless viscous oil, which solidified on cooling (white crystals, 1.95 g, 25% overall yield): mp 
72-74 °C (Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 0.84 (t, 3H, J=7.3 Hz, CH3(CH2)3), 1.05-1.17 (complex m, 
 
2H, CH3CH2CH2CH2), 1.19 (t, 3H, J=7.1 Hz, CO2CH2CH3), 1.26-1.39 (complex m, 2H, CH3CH2(CH2)2), 1.98-2.23 (dm, 
2H, CH3(CH2)2CH2), 2.26-2.48 (br s, 1H, NHCH2CO2CH2CH3), 3.15 (~s, 2H, NHCH2CO2CH2CH3), 4.03-4.18 (q, 2H, 
J=7.1 Hz, CO2CH2CH3), 6.64 (s, 1H, CONHH), 6.96 (s, 1H, CONHH), 7.16-7.32 (complex m, 3H, aromatic H), 7.41-
7.50 (complex m, 2H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 13.9 (CH3(CH2)3), 14.0 (CO2CH2CH3), 22.8 
(CH3CH2(CH2)2), 25.3 (CH3CH2CH2CH2), 33.1 (CH3(CH2)2CH2), 44.9 (NHCH2CO2CH2CH3), 60.9 (CO2CH2CH3), 67.1 
(C6H5(n-C4H9)CNH), 126.3, 127.3, 128.4 (2,3,4,5,6-aromatic C), 141.0 (1-aromatic C), 171.9 (CO2CH2CH3), 176.8 
(CONH2). Anal. Calcd for C16H24N2O3: C, 65.72; H, 8.27; N, 9.58; Found: C, 65.95; H, 8.35; N, 9.39. 
4.1.5. N-[[1-Aminocarbonyl-1-(4-fluorophenyl)]ethyl]glycine ethyl ester 26 
Prepared from 4-fluoroacetophenone 21 (3.67 g, 26.6 mmol) according to the method described for compound 
23. The crude oil was purified by column chromatography on silica gel eluting first with AcOEt-n-hexane 1:1 and 
then AcOEt to afford the title compound 26 as a light-yellow viscous oil, which solidified on standing (2.14 g, 
30% overall yield). An analytical sample was obtained as white crystals upon dissolution of the product in Et2O 
and n-pentane-mediated precipitation. Mp 90-92 °C. 1H NMR (600 MHz, CDCl3) δ 1.23 (t, 3H, J=7.1 Hz, 
CO2CH2CH3), 1.68 (s, 3H, CH3), 2.24 (s, 1H, NHCH2CO2CH2CH3), 3.24 (~s, 2H, NHCH2CO2CH2CH3), 4.10-4.17 (q, 2H, 
J=7.1 Hz, CO2CH2CH3), 6.18 (s, 1H, CONHH), 7.01 (t, 2H, J=8.7 Hz, 3,5-aromatic H), 7.03 (s, 1H, CONHH), 7.43-7.49 
(~q, 2H, J=5.3 Hz, 2,6-aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.2 (CO2CH2CH3), 23.1 (CH3), 45.6 
(NHCH2CO2CH2CH3), 61.3 (CO2CH2CH3), 64.4 (4-FC6H4(CH3)CNH), 115.2, 115.7 (d, JC-F=21.2 Hz, 3,5-aromatic C), 
128.2, 128.4 (d, JC-F=8.1 Hz, 2,6-aromatic C), 137.6, 137.7 (d, JC-F=3.3 Hz, 1-aromatic C), 159.8, 164.7 (d, JC-F=245 
Hz, 4-aromatic C), 172.3 (CO2CH2CH3), 177.4 (CONH2). Anal. Calcd for C13H17FN2O3: C, 58.20; H, 6.39; N, 10.44; 
Found: C, 58.05; H, 6.45; N, 10.62. 
4.1.6. N-[[1-Aminocarbonyl-1-(4-nitrophenyl)]ethyl]glycine ethyl ester 27 
Prepared from 4-nitroacetophenone 22 (4.39 g, 26.6 mmol) according to the method described for compound 
23. The resulting crude oil was purified by column chromatography eluting first with AcOEt-n-hexane 1:1 to 
remove the starting 4-nitroacetophenone 22. Further elution with AcOEt-n-hexane 2:1 followed by AcOEt 
afforded first the respective 2,6-diketopiperazine 46 (white crystals, 740 mg, 11% yield from 22), and then the 
title compound 27 as an off-yellow viscous oil, which solidified on standing (4.33 g, 55% overall yield). An 
analytical sample was obtained as slightly off-yellow crystals upon dissolution of the product in AcOEt-Et2O 1:5 
and n-pentane-mediated precipitation. Mp 83-85 °C. 1H NMR (400 MHz, CDCl3) δ 1.22 (t, 3H, J=7.2 Hz, 
CO2CH2CH3), 1.72 (s, 3H, CH3), 2.20-2.46 (br s, 1H, NHCH2CO2CH2CH3), 3.25 (~s, 2H, NHCH2CO2CH2CH3), 4.08-4.20 
(q, 2H, J=7.1 Hz, CO2CH2CH3), 6.34 (s, 1H, CONHH), 7.15 (s, 1H, CONHH), 7.68 (d, 2H, J=8.9 Hz, 2,6-aromatic H), 
8.17 (d, 2H, J=8.9 Hz, 3,5-aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.2 (CO2CH2CH3), 23.3 (CH3), 45.6 
(NHCH2CO2CH2CH3), 61.5 (CO2CH2CH3), 65.0 (4-NO2C6H4(CH3)CNH), 123.7 (3,5-aromatic C), 127.7 (2,6-aromatic 
C), 147.3, 149.2 (1,4-aromatic C), 172.0 (CO2CH2CH3), 176.2 (CONH2). Anal. Calcd for C13H17N3O5: C, 52.87; H, 
5.80; N, 14.23; Found: C, 52.59; H, 5.82; N, 14.52. 
4.1.7. 3-Methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid benzyl ester 28 
A stirred solution of the amide-ester derivative 23 (1 g, 4 mmol) in dry THF (40 mL) was cooled in an ice-water 
bath and treated portionwise with potassium bis(trimethylsilyl)amide (798 mg, 4.0 mmol) under argon. After 2 
h of stirring at room temperature under argon, the mixture was concentrated to dryness under reduced 
pressure, and the residue (potassium imidate salt) was dissolved in dry DMF (40 mL). To this solution, benzyl 
bromoacetate (962 mg, 4.2 mmol) dissolved in dry DMF (10 mL) was added dropwise, and the mixture was 
stirred at room temperature for 48 h under argon. The reaction mixture was then poured into ice-water (80 mL) 
and extracted with Et2O (4 × 60 mL). The combined organic extracts were washed with brine (2 × 50 mL), dried 
(Na2SO4) and concentrated to dryness under reduced pressure. The remaining crude thick oil was purified by 
flash column chromatography with AcOEt-Et2O-n-hexane 0.5:1:1, as eluent, to afford the title compound 28 as 
a pale pink viscous oil (1.13 g, 81%); 1H NMR (400 MHz, CDCl3) δ 1.57 (s, 3H, CH3), 2.10-2.39 (br s, 1H, 4-H), 3.40 
(d, 1H, J=18.5 Hz, 5-H), 3.61 (d, 1H, J=18.5 Hz, 5-H), 4.45-4.65 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.11 (s, 2H, 
 
CO2CH2Ph), 7.22-7.42 (m, 10H, aromatic H); 13C NMR (100 MHz, CDCl3) δ 28.7 (CH3), 40.3 (CH2CO2CH2Ph), 46.0 
(5-C), 62.6 (3-C), 67.3 (CO2CH2Ph), 125.7, 128.2, 128.4, 128.6, 128.9, 135.1, 138.7 (aromatic C), 167.7 
(CO2CH2Ph), 171.3, 173.6 (2,6-C); HRMS (APCI+): [M+H]+ calcd for C20H20N2O4, 353.1501, found 353.1494. 
4.1.8. 2,6-Dioxo-3-phenyl-3-propyl-1-piperazineacetic acid benzyl ester 29 
Prepared from the amide-ester derivative 24 (3.2 g, 11.5 mmol) following the procedure described for 
compound 28. The crude yellow solid was purified by column chromatography on silica gel with AcOEt-n-hexane 
1:2, as eluent, to afford the title compound 29 as a slightly off-yellow solid (3.98 g, 91%): mp 63-65 °C (Et2O-n-
pentane); 1H NMR (400 MHz, CDCl3) δ 0.88 (t, 3H, J=7.2 Hz, CH3(CH2)2), 1.20-1.38 (m, 2H, CH3CH2CH2), 1.80-2.13 
(dm, 2H, CH3CH2CH2), 2.12-2.50 (br s, 1H, 4-H), 3.55 (d, 1H, J=18.4 Hz, 5-H), 3.74 (d, 1H, J=18.4 Hz, 5-H), 4.51-
4.74 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.19 (s, 2H, CO2CH2Ph), 7.27-7.51 (complex m, 10H, aromatic H); 13C 
NMR (50 MHz, CDCl3) δ 14.3 (CH3(CH2)2), 17.3 (CH3CH2CH2), 40.4 (CH2CO2CH2Ph), 44.1 (CH3CH2CH2), 46.0 (5-C), 
65.9 (3-C), 67.4 (CO2CH2Ph), 126.2, 128.3, 128.4, 128.6, 128.8, 129.0, 135.3, 137.8 (aromatic C), 167.9 
(CO2CH2Ph), 171.3, 173.2 (2,6-C). Anal. Calcd for C22H24N2O4: C, 69.45; H, 6.36; N, 7.36; Found: C, 69.67; H, 6.42; 
N, 7.07. 
4.1.9. 3-Butyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid benzyl ester 30 
Prepared from the amide-ester derivative 25 (2.5 g, 8.55 mmol) following the procedure described for 
compound 28. The crude yellowish solid was purified by flash column chromatography with AcOEt-n-hexane 
1:2, as eluent, to afford the title compound 30 as a white solid (2.81 g, 83%): mp 92-94 °C (Et2O-n-pentane); 1H 
NMR (400 MHz, CDCl3) δ 0.78 (t, 3H, J=6.8 Hz, CH3(CH2)3), 1.10-1.28 (m, 4H, CH3CH2CH2CH2), 1.76-2.08 (dm, 2H, 
CH3(CH2)2CH2), 2.09-2.42 (br s, 1H, 4-H), 3.47 (d, 1H, J=18.4 Hz, 5-H), 3.66 (d, 1H, J=18.4 Hz, 5-H), 4.47-4.62 (q, 
AB, 2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.11 (s, 2H, CO2CH2Ph), 7.15-7.45 (m, 10H, aromatic H); 13C NMR (50 MHz, 
CDCl3) δ 14.0 (CH3(CH2)3), 22.9 (CH3CH2(CH2)2), 26.0 (CH3CH2CH2CH2), 40.3 (CH2CO2CH2Ph), 41.7 (CH3(CH2)2CH2), 
45.9 (5-C), 65.8 (3-C), 67.4 (CO2CH2Ph), 126.2, 128.3, 128.6, 128.7, 128.9, 135.3, 137.8 (aromatic C), 167.8 
(CO2CH2Ph), 171.3, 173.1 (2,6-C). Anal. Calcd for C23H26N2O4: C, 70.03; H, 6.64; N, 7.10; Found: C, 70.27; H, 6.80; 
N, 6.82. 
4.1.10. 3-(4-Fluorophenyl)-3-methyl-2,6-dioxo-1-piperazineacetic acid benzyl ester 31 
Prepared from the amide-ester derivative 26 (2.5 g, 9.32 mmol) following the procedure described for 
compound 28. The crude yellow oil was purified by flash column chromatography with AcOEt-n-hexane 1:2, as 
eluent, to afford the title compound 31 as a light-yellow viscous oil (2.52 g, 73%): 1H NMR (400 MHz, CDCl3) δ 
1.63 (s, 3H, CH3), 2.86 (br s, 1H, 4-H), 3.45 (d, 1H, J=18.6 Hz, 5-H), 3.70 (d, 1H, J=18.6 Hz, 5-H), 4.54-4.71 (q, AB, 
2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.19 (s, 2H, CO2CH2Ph), 7.01 (t, 2H, J=8.7 Hz, 3,5-H for 4-FC6H4), 7.30-7.50 
(complex m, 7H, C6H5, 2,6-H for 4-FC6H4); 13C NMR (50 MHz, CDCl3) δ 29.0 (CH3), 40.4 (CH2CO2CH2Ph), 45.9 (5-C), 
62.3 (3-C), 67.5 (CO2CH2Ph), 115.7, 116.2 (d, JC-F=21.4 Hz, 3,5-C for 4-FC6H4), 127.7, 127.9 (d, JC-F=8.1 Hz, 2,6-C 
for 4-FC6H4), 128.4, 128.6, 128.8 (2,3,4,5,6-C for C6H5), 134.5, 134.6 (d, JC-F=3.2 Hz, 1-C for 4-FC6H4), 135.2 (1-C 
for C6H5), 160.1, 165.0 (d, JC-F=246 Hz, 4-C for 4-FC6H4), 167.8 (CO2CH2Ph), 171.2, 173.6 (2,6-C); HRMS (ESI): 
[M+H]+, [M+Na]+ calcd for C20H19FN2O4, 371.1407, 393.1227, found 371.1411, 393.1229. 
4.1.11. 3-Methyl-3-(4-nitrophenyl)-2,6-dioxo-1-piperazineacetic acid 4-methoxybenzyl ester 32 
Prepared from the amide-ester derivative 27 (2 g, 6.77 mmol) following the procedure described for compound 
28, but with 4-methoxybenzyl bromoacetate instead of benzyl bromoacetate. The crude yellow solid was 
purified by column chromatography on silica gel eluting with AcOEt-n-hexane 1:1→1:0 to afford the title 
compound 32 as an off-yellow solid (2.4 g, 83%): mp 128-130 °C (AcOEt/Et2O-n-pentane); 1H NMR (400 MHz, 
CDCl3) δ 1.67 (s, 3H, CH3), 2.13-2.38 (br s, 1H, 4-H), 3.40 (d, 1H, J=18.7 Hz, 5-H), 3.76 (d, 1H, J=18.7 Hz, 5-H), 3.81 
(s, 3H, OCH3), 4.52-4.68 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2C6H4OCH3-4), 5.11 (s, 2H, CO2CH2C6H4OCH3-4), 6.88 
(d, 2H, J=8.7 Hz, 3,5-H for 4-CH3OC6H4), 7.26 (d, 2H, J=8.7 Hz, 2,6-H for 4-CH3OC6H4), 7.69 (d, 2H, J=9.0 Hz, 2,6-H 
for 4-NO2C6H4), 8.16 (d, 2H, J=9.0 Hz, 3,5-H for 4-NO2C6H4); 13C NMR (50 MHz, CDCl3) δ 29.0 (CH3), 40.6 
(CH2CO2CH2C6H4OCH3-4), 45.9 (5-C), 55.4 (OCH3), 62.7 (3-C), 67.6 (CO2CH2C6H4OCH3-4), 114.2, 124.3, 127.2, 
 
130.3, 146.2, 148.0, 160.1 (aromatic C), 167.6 (CO2CH2C6H4OCH3-4), 170.6, 172.7 (2,6-C). Anal. Calcd for 
C21H21N3O7: C, 59.01; H, 4.95; N, 9.83; Found: C, 58.78; H, 4.89; N, 10.02. 
4.1.12. 3-Methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid 33 
10% Pd on charcoal (132 mg) was added to a solution of benzyl ester 28 (1.1 g, 3.12 mmol) in abs EtOH (78 mL). 
After 3 h of shaking under an atmosphere of 50 psi hydrogen at room temperature, the catalyst was removed 
by filtration and washed with EtOH (3 × 15 mL). The combined filtrates were concentrated to dryness under 
reduced pressure to afford the title compound 33 as a white foamy solid, which strongly binds the 
aforementioned solvent. Removal of the entrapped solvent upon drying at 62-64 °C under high vacuum (10-2 
mmHg) in an Abderhalden apparatus gave 33 as a glass solid (814 mg, almost quantitative yield): 1H NMR (400 
MHz, CDCl3) δ 1.67 (s, 3H, CH3), 3.48 (d, 1H, J=18.5 Hz, 5-H), 3.75 (d, 1H, J=18.5 Hz, 5-H), 4.52-4.70 (q, AB, 2H, 
JAB≃17.0 Hz, CH2CO2H), 7.0 (s, 2H, 4-H, CO2H), 7.30-7.48 (m, 5H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 28.4 
(CH3), 40.2 (CH2CO2H), 45.8 (5-C), 62.8 (3-C), 125.7, 128.3, 129.0 (2,3,4,5,6-aromatic C), 138.4 (1-aromatic C) 
171.1, 172.6, 173.4 (CO2H, 2,6-C). The hydrochloride salt (33·HCl) was prepared by treating a clear diethyl ether 
solution of 33 with saturated solution of HCl in Et2O under ice cooling. The white precipitate was collected by 
vacuum filtration, triturated with Et2O and dried in vacuo. Mp 224-226 °C (dec). Anal. Calcd for C13H15ClN2O4: C, 
52.27; H, 5.06; N, 9.38; Found: C, 51.85; H, 5.26; N, 9.62. 
4.1.13. 2,6-Dioxo-3-phenyl-3-propyl-1-piperazineacetic acid 34 
Prepared from benzyl ester 29 (2.46 g, 6.47 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 295 mg) in abs 
EtOH (160 mL) as described for compound 33. The resulting off-white foamy solid was triturated with a diethyl 
ether-n-pentane 1:1 mixture giving the title compound 34 as white crystals (1.84 g, 98%). Recrystallization from 
Et2O-n-pentane furnished an analytical sample, which had mp 131-133 °C. 1H NMR (400 MHz, CDCl3) δ 0.88 (t, 
3H, J≃7.2 Hz, CH3(CH2)2), 1.22-1.38 (m, 2H, CH3CH2CH2), 1.83-2.14 (dm, 2H, CH3CH2CH2), 3.55 (d, 1H, J=18.4 Hz, 
5-H), 3.77 (d, 1H, J=18.4 Hz, 5-H), 4.50-4.70 (q, AB, 2H, JAB=17.0 Hz, CH2CO2H), 6.65 (s, 2H, 4-H, CO2H), 7.22-7.48 
(m, 5H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.3 (CH3(CH2)2), 17.3 (CH3CH2CH2), 40.1 (CH2CO2H), 43.9 
(CH3CH2CH2), 45.8 (5-C), 65.9 (3-C), 126.2, 128.4, 129.0 (2,3,4,5,6-aromatic C), 137.5 (1-aromatic C), 171.3, 173.0 
(CO2H, 2,6-C). Anal. Calcd for C15H18N2O4: C, 62.06; H, 6.25; N, 9.65; Found: C, 61.79; H, 6.30; N, 9.96. 
4.1.14. 3-Butyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid 35 
Prepared from benzyl ester 30 (2.7 g, 6.84 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 324 mg) in abs EtOH-
AcOEt 3:1 (170 mL) as described for compound 33. The resulting glass solid was triturated with Et2O (50 mL) to 
give the title compound 35 as an off-white crystalline solid (2 g, 96%). Recrystallization of specimen of this 
material from Et2O-n-pentane furnished an analytical sample as white crystals, mp 121-123 °C. 1H NMR (400 
MHz, CDCl3) δ 0.86 (t, 3H, J=6.6 Hz, CH3(CH2)3), 1.18-1.37 (m, 4H, CH3CH2CH2CH2), 1.84-2.18 (sym dm, 2H, 
CH3(CH2)2CH2), 3.56 (d, 1H, J=18.5 Hz, 5-H), 3.77 (d, 1H, J=18.5 Hz, 5-H), 4.52-4.70 (q, AB, 2H, JAB=17.0 Hz, 
CH2CO2H), 6.80 (s, 2H, 4-H, CO2H), 7.25-7.52 (m, 5H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.0 (CH3(CH2)3), 
23.0 (CH3CH2(CH2)2), 26.1 (CH3CH2CH2CH2), 40.1 (CH2CO2H), 41.6 (CH3(CH2)2CH2), 45.8 (5-C), 65.9 (3-C), 126.2, 
128.3, 129.0 (2,3,4,5,6-aromatic C), 137.6 (1-aromatic C), 171.3, 173.0, 173.4 (CO2H, 2,6-C). Anal. Calcd for 
C16H20N2O4: C, 63.14; H, 6.62; N, 9.20; Found: C, 62.90; H, 6.68; N, 9.48. 
4.1.15. 3-(4-Fluorophenyl)-3-methyl-2,6-dioxo-1-piperazineacetic acid 36 
Prepared from benzyl ester 31 (2.47 g, 6.67 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 296 mg) in abs 
EtOH (167 mL) as described for compound 33. The obtained white foamy solid strongly binds the hydrogenation 
solvent. Removal of the entrapped solvent as in 33 gave the title compound 36 as a white amorphous solid (1.86 
g, almost quantitative yield). A small quantity of this material was dissolved in AcOEt-Et2O 1:1, and the clear 
solution was concentrated to dryness in vacuo. Trituration of the residue with a diethyl ether-n-pentane 1:1 
mixture provided an analytical sample as white crystals. Mp 150-153 °C. 1H NMR (400 MHz, DMS0-d6) δ 1.50 (s, 
3H, CH3), 3.16 (d, 1H, J=18.4 Hz, 5-H), 3.62 (d, 1H, J=18.4 Hz, 5-H), 3.25-4.25 (v br s, 2H, 4-H, CO2H), 4.30-4.45 (q, 
AB, 2H, JAB≃17.3 Hz, CH2CO2H), 7.19 (t like, 2H, J=7.3, 8.4 Hz, 3,5-aromatic H), 7.47 (t like, 2H, J=5.3, 7.5 Hz, 2,6-
 
aromatic H); 13C NMR (50 MHz, DMSO-d6) δ 28.3 (CH3), 40.2 (CH2CO2H), 45.6 (5-C), 61.6 (3-C), 115.2, 115.7 (d, 
JC-F=21.2 Hz, 3,5-aromatic C), 128.0, 128.2 (d, JC-F=7.9 Hz, 2,6-aromatic C), 136.2 (1-aromatic C), 159.2, 164.1 (d, 
JC-F=243 Hz, 4-aromatic C), 169.1 (CO2H), 171.3, 173.5 (2,6-C). Anal. Calcd for C13H13FN2O4: C, 55.71; H, 4.68; N, 
10.0; Found: C, 55.98; H, 4.46; N, 9.66. 
4.1.16. 3-Methyl-3-phenyl-2,6-piperazinedione 42 
The amide-ester derivative 23 (500 mg, 2 mmol) was subjected to treatment with potassium 
bis(trimethylsilyl)amide (399 mg, 2.0 mmol) in dry THF (20 mL) as described in 28. The reaction was then 
quenched by adding trifluoroacetic acid (230 mg, 2 mmol, 1 equiv), and the solvent was evaporated to dryness 
under reduced pressure. Purification of the residual viscous oil by column chromatography on silica gel with 
AcOEt-Et2O-n-hexane 1:1:0.5, as eluent, afforded the title compound 42 as a white crystalline solid (380 mg, 
93%): mp 131-133 °C (AcOEt/Et2O-n-pentane) (lit[10] mp 133-133.5 °C); 1H NMR (400 MHz, CDCl3) δ 1.63 (s, 3H, 
CH3), 2.31 (s, 1H, 4-H), 3.38 (d, 1H, J=18.6 Hz, 5-H), 3.62 (d, 1H, J=18.6 Hz, 5-H), 7.27-7.53 (complex m, 5H, 
aromatic H), 8.79 (s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 28.1 (CH3), 45.9 (5-C), 62.3 (3-C), 125.7, 128.4, 129.2 
(2,3,4,5,6-aromatic C), 138.6 (1-aromatic C) 172.9, 174.5 (2,6-C). Anal. Calcd for C11H12N2O2: C, 64.69; H, 5.92; N, 
13.72; Found: C, 64.66; H, 5.82; N, 13.88. 
4.1.17. 3-Phenyl-3-propyl-2,6-piperazinedione 43 
Prepared from the amide-ester derivative 24 (1.17 g, 4.2 mmol) in the same manner as for 42. The resulting 
crude oil was purified by column chromatography on silica gel with AcOEt-n-hexane 1:1, as eluent, to afford the 
title compound 43 as a glass oil (930 mg, 95%). Crystallization of this product material upon treatment with a 
diethyl ether-n-pentane 1:1 mixture, and subsequent recrystallization (Et2O-n-pentane) gave a white crystalline 
solid, which melted at 80-82 °C (lit[10] mp 75-77.5 °C) after drying at room temperature in vacuo. This solid 
product strongly binds Et2O as indicated by its 1H NMR spectrum. Removal of the crystal solvent upon drying at 
62-64 °C under high vacuum (10-2 mmHg) in an Abderhalden apparatus restored the solid material to the initial 
glass oil state. 1H NMR (400 MHz, CDCl3) δ 0.8 (t, 3H, J=7.3 Hz, CH3(CH2)2), 1.10-1.32 (m, 2H, CH3CH2CH2), 1.77-
2.0 (dm, 2H, CH3CH2CH2), 2.09-2.32 (br s, 1H, 4-H), 3.39 (d, 1H, J=18.5 Hz, 5-H), 3.58 (d, 1H, J=18.5 Hz, 5-H), 7.17-
7.47 (m, 5H, aromatic H), 8.53 (s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 14.3 (CH3(CH2)2), 17.3 (CH3CH2CH2), 43.2 
(CH3CH2CH2), 45.7 (5-C), 65.3 (3-C), 126.1, 128.3, 129.0 (2,3,4,5,6-aromatic C), 137.4 (1-aromatic C), 172.7, 174.0 
(2,6-C); ES+ MS:m/z 233.2 [M+H]+. 
4.1.18. 3-Butyl-3-phenyl-2,6-piperazinedione 44 
Prepared from the amide-ester derivative 25 (2.24 g, 7.66 mmol) in the same manner as for 42. The resulting 
crude oil was purified by flash column chromatography eluting with AcOEt-n-hexane 1:2 to afford the title 
compound 44 as a slightly off-white solid (1.81 g, 96%). To obtain an analytical sample, a small quantity of this 
material was recrystallized from Et2O-n-pentane giving a cotton like solid, which melted at 72-74 °C after drying 
at room temperature in vacuo. This solid material strongly binds the recrystallization solvents as indicated by its 
1H NMR spectrum. Removal of the crystal solvents upon drying at 62-64 °C under high vacuum (10-2 mmHg) 
provided a white crystalline solid, which had mp 79-82 °C. 1H NMR (400 MHz, CDCl3) δ 0.86 (t, 3H, J=6.8 Hz, 
CH3(CH2)3), 1.16-1.37 (m, 4H, CH3CH2CH2CH2), 1.83-2.13 (dm, 2H, CH3(CH2)2CH2), 2.18-2.36 (br s, 1H, 4-H), 3.47 
(d, 1H, J=18.1 Hz, 5-H), 3.66 (d, 1H, J=18.5 Hz, 5-H), 7.28-7.53 (m, 5H, aromatic H), 7.96 (s, 1H, 1-H); 13C NMR (50 
MHz, CDCl3) δ 14.0 (CH3(CH2)3), 22.9 (CH3CH2(CH2)2), 26.1 (CH3CH2CH2CH2), 40.9 (CH3(CH2)2CH2), 45.8 (5-C), 65.3 
(3-C), 126.1, 128.3, 129.1 (2,3,4,5,6-aromatic C), 137.5 (1-aromatic C), 172.4, 173.8 (2,6-C). Anal. Calcd for 
C14H18N2O2: C, 68.27; H, 7.37; N, 11.37; Found: C, 68.42; H, 7.64; N, 11.09. 
4.1.19. 3-(4-Fluorophenyl)-3-methyl-2,6-piperazinedione 45 
Prepared from the amide-ester derivative 26 (500 mg, 1.86 mmol) in the same manner as for 42. The resulting 
crude solid was purified by flash column chromatography eluting with AcOEt-n-hexane 2:1 to afford the title 
compound 45 as a white crystalline solid (380 mg, 92%): mp 151-153 °C. (AcOEt/Et2O 1:20-n-pentane); 1H NMR 
(600 MHz, DMSO-d6) δ 1.43 (s, 3H, CH3), 2.98-3.04 (q, 1H, J=10.7 Hz, 5-H), 3.40-3.45 (dd, 1H, J=4.5, 18.3 Hz, 5-
 
H), 3.79-3.83 (dd, 1H, J=4.5, 10.6 Hz, 4-H), 7.21 (~t, 2H, J=8.8 Hz, 3,5-aromatic H), 7.40-7.47 (~q, 2H, J=5.5 Hz, 
2,6-aromatic H), 11.07 (s, 1H, 1-H); 13C NMR (50 MHz, DMSO-d6) δ 27.7 (CH3), 45.4 (5-C), 60.8 (3-C), 115.4, 115.8 
(d, JC-F=21.3 Hz, 3,5-aromatic C), 127.5, 127.7 (d, JC-F=8.1 Hz, 2,6-aromatic C), 136.3 (1-aromatic C), 159.1, 164.0 
(d, JC-F=242 Hz, 4-aromatic C), 173.1, 174.8 (2,6-C). Anal. Calcd for C11H11FN2O2: C, 59.45; H, 4.99; N, 12.61; Found: 
C, 59.41; H, 4.89; N, 12.76. 
4.1.20. 3-Methyl-3-(4-nitrophenyl)-2,6-piperazinedione 46 
Prepared from the amide-ester derivative 27 (1 g, 3.39 mmol) in the same manner as for 42. The resulting crude 
solid was purified by column chromatography on silica gel with AcOEt-n-hexane 2:1, as eluent, to afford the title 
compound 46 as an off-yellow solid (770 mg, 91%): mp 211-213 °C. (MeOH-Et2O); 1H NMR (400 MHz, DMSO-d6) 
δ 1.47 (s, 3H, CH3), 2.98-3.11 (q, 1H, J=10.8 Hz, 5-H), 3.42-3.52 (dd, 1H, J=4.5, 18.4 Hz, 5-H), 3.92-4.02 (dd, 1H, 
J=4.4, 10.7 Hz, 4-H), 7.69 (d, 2H, J=8.8 Hz, 2,6-aromatic H), 8.25 (d, 2H, J=8.0 Hz, 3,5-aromatic H), 11.22 (s, 1H, 
1-H); 13C NMR (50 MHz, DMSO-d6) δ 27.4 (CH3), 45.4 (5-C), 61.3 (3-C), 124.0 (3,5-aromatic C), 127.0 (2,6-aromatic 
C), 147.1, 148.0 (1,4-aromatic C), 172.8, 174.1 (2,6-C). Anal. Calcd for C11H11N3O4: C, 53.01; H, 4.45; N, 16.86; 
Found: C, 52.88; H, 4.61; N, 17.04. 
4.1.21. 3,4-Dimethyl-3-phenyl-2,6-piperazinedione 47 
A solution of compound 42 (721 mg, 3.53 mmol) and aqueous formaldehyde 37% (2.2 mL) in methanol (22 mL) 
was stirred at room temperature  for 3 h, and NaCNBH3 (398 mg, 6.33 mmol) was then added in one portion. 
After 20 min of stirring, the pH of the reaction mixture was adjusted to 6-7 by dropwise addition of acetic acid. 
Stirring was continued for 4 h at room temperature with occasional addition of acetic acid to maintain the pH 
at 6-7. Methanol was removed by evaporation in vacuo, and the residue was treated with water (10 mL) 
followed by 1N aq NaOH and solid Na2CO3 until the pH was adjusted to 8. Subsequently the mixture was 
extracted with CH2Cl2 (3 ×35 mL), and the combined organic extracts were washed with brine (2 ×35 mL), dried 
(Na2SO4) and concentrated to dryness under reduced pressure. The remaining viscous oil solidified after a few 
minutes of standing. The resulting crude solid was purified over a column of flash silica eluting with AcOEt-n-
hexane-Et2O 1:1:0.5 to afford the title compound 47 as a white crystalline solid (593 mg, 77%): mp 127-129 °C. 
(Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 1.63 (s, 3H, 3-CH3), 2.52 (s, 3H, 4-CH3), 3.27-3.61 (q, AB, 2H, 
JAB=18.2 Hz, 5-H), 7.27-7.47 (m, 5H, aromatic H), 8.79 (br s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 23.5 (3-CH3), 
38.3 (4-CH3), 54.9 (5-C), 67.7 (3-C), 126.0, 128.3, 129.0 (2,3,4,5,6-aromatic C), 140.5 (1-aromatic C), 171.4, 174.1 
(2,6-C). Anal. Calcd for C12H14N2O2: C, 66.04; H, 6.47; N, 12.84; Found: C, 65.91; H, 6.62; N, 12.62. 
4.1.22. 4-Methyl-3-phenyl-3-propyl-2,6-piperazinedione 48 
Prepared by reductive methylation of diketopiperazine 43 (920 mg, 3.96 mmol) as described for compound 47. 
The crude thick oil was purified by column chromatography on silica gel with AcOEt-n-hexane 1:3, as eluent, to 
afford a colorless viscous oil, which solidified on standing (white crystals, 860 mg, 88% yield): mp 116-118 °C 
(Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 0.75 (t, 3H, J=7.4 Hz, CH3(CH2)2), 1.02-1.20 (m, 2H, CH3CH2CH2), 
1.77-2.08 (dm, 2H, CH3CH2CH2), 2.43 (s, 3H, 4-CH3), 3.21-3.66 (q, AB, 2H, JAB=18.2 Hz, 5-H), 7.17-7.36 (m, 5H, 
aromatic H), 8.82 (s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 14.3 (CH3(CH2)2), 16.2 (CH3CH2CH2), 38.1 (4-CH3), 38.3 
(CH3CH2CH2), 55.1 (5-C), 70.0 (3-C), 126.9, 128.2, 128.7 (2,3,4,5,6-aromatic C), 136.9 (1-aromatic C), 171.4, 174.0 
(2,6-C). Anal. Calcd for C14H18N2O2: C, 68.27; H, 7.37; N, 11.37; Found: C, 68.41; H, 7.21; N, 11.51. 
4.1.23. 3-Butyl-4-methyl-3-phenyl-2,6-piperazinedione 49 
Prepared by reductive methylation of diketopiperazine 44 (900 mg, 3.65 mmol) as described for compound 47. 
The crude yellowish thick oil was purified over a column of flash silica eluting with AcOEt-n-hexane 1:4 to afford 
the title compound 49 as a colorless viscous oil, which solidified on standing under cooling (white crystals, 810 
mg, 85% yield): mp 67-69 °C. (Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 0.82 (t, 3H, J≃7.0 Hz, CH3(CH2)3), 
1.05-1.31 (m, 4H, CH3CH2CH2CH2), 1.89-2.15 (dm, 2H, CH3(CH2)2CH2), 2.50 (s, 3H, 4-CH3), 3.26-3.76 (q, AB, 2H, 
JAB=18.2 Hz, 5-H), 7.30-7.52 (m, 5H, aromatic H), 8.48 (s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 14.0 (CH3(CH2)3), 
22.9 (CH3CH2(CH2)2), 24.8 (CH3CH2CH2CH2), 35.8 (CH3(CH2)2CH2), 38.1 (4-CH3), 55.1 (5-C), 70.1 (3-C), 126.9, 128.3, 
 
128.7 (2,3,4,5,6-aromatic C), 136.8 (1-aromatic C), 171.2, 173.9 (2,6-C). Anal. Calcd for C15H20N2O2: C, 69.20; H, 
7.74; N, 10.76; Found: C, 69.32; H, 7.63; N, 10.98. 
4.1.24. 3-(4-Fluorophenyl)-3,4-dimethyl-2,6-piperazinedione 50 
Prepared by reductive methylation of diketopiperazine 45 (1.05 g, 4.73 mmol) as described for compound 47. 
The crude yellowish thick oil was purified by column chromatography on silica gel with AcOEt-n-hexane 1:3, as 
eluent, to afford the title compound as a colorless viscous oil, which solidified on standing (white crystals, 765 
mg, 69% yield): mp 116-118 °C. (Et2O-n-pentane); 1H NMR (600 MHz, CDCl3) δ 1.60 (s, 3H, 3-CH3), 2.48 (s, 3H, 4-
CH3), 3.30-3.57 (q, AB, 2H, JAB=18.1 Hz, 5-H), 7.04 (t like, 2H, J=8.6 Hz, 3,5-aromatic H), 7.40-7.45 (q like, 2H, J=5.2 
Hz, 2,6-aromatic H), 8.64 (s, 1H, 1-H); 13C NMR (50 MHz, CDCl3) δ 23.0 (3-CH3), 38.3 (4-CH3),  54.7 (5-C), 67.1 (3-
C), 115.7, 116.1 (d, JC-F=21.4 Hz, 3,5-aromatic C), 127.8, 128.0 (d, JC-F=7.9 Hz, 2,6-aromatic C), 136.3 (1-aromatic 
C), 160.0, 165.0 (d, JC-F=246 Hz, 4-aromatic C), 171.1, 174.0 (2,6-C). Anal. Calcd for C12H13FN2O2: C, 61.01; H, 5.55; 
N, 11.86; Found: C, 61.18; H, 5.45; N, 12.08. 
4.1.25. 3,4-Dimethyl-3-(4-nitrophenyl)-2,6-piperazinedione 51 
Prepared by reductive methylation of diketopiperazine 46 (1.06 g, 4.25 mmol) in THF-MeOH 1:1 (50 mL) as 
described for compound 47. The crude viscous was purified by column chromatography on silica gel with AcOEt-
n-hexane 1:4 to 1:2 to afford the title compound 51 as a white crystalline solid (925 mg, 83%): mp 136-138 °C. 
(AcOEt/Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 1.65 (s, 3H, 3-CH3), 2.50 (s, 3H, 4-CH3), 3.36-3.57 (q, AB, 
2H, JAB=18.1 Hz, 5-H), 7.69 (d, 2H, J=9.0 Hz, 2,6-aromatic H), 8.23 (d, 2H, J=9.0 Hz, 3,5-aromatic H), 8.55 (s, 1H, 
1-H); 13C NMR (50 MHz, CDCl3) δ 22.4 (3-CH3), 38.3 (4-CH3), 54.7 (5-C), 67.5 (3-C), 124.3 (3,5-aromatic C), 127.4 
(2,6-aromatic C), 148.0 (1,4-aromatic C), 170.2, 173.0 (2,6-C). Anal. Calcd for C12H13N3O4: C, 54.75; H, 4.98; N, 
15.96; Found: C, 54.59; H, 4.82; N, 16.14. 
4.1.26. 3,4-Dimethyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid benzyl ester 52 
A stirred solution of diketopiperazine 47 (1.13 g, 5.18 mmol) in dry DMF (30 mL) was treated portionwise with 
sodium hydride (149 mg, 6.22 mmol). After 1 h of stirring at room temperature under argon, benzyl 
bromoacetate (1.25 g, 5.43 mmol) dissolved in dry DMF (6 mL) was added dropwise. Stirring was continued at 
room temperature for 48 h under argon, and the reaction mixture was then poured into ice-water (75 mL) and 
extracted with ethyl acetate (4 × 60 mL). The combined organic extracts were washed with brine (2 × 60 mL), 
dried (Na2SO4), and concentrated to dryness in vacuo. The residual thick oil was purified by flash column 
chromatography eluting with AcOEt-n-hexane 1:2 to afford the title compound 52 as a light-yellow viscous oil, 
which solidified on standing under cooling (1.62 g, 85%). An analytical sample was obtained as white crystals 
upon dissolution of the product in Et2O and n-pentane-mediated precipitation. Mp 90-92 °C. 1H NMR (400 MHz, 
CDCl3) δ 1.65 (s, 3H, 3-CH3), 2.54 (s, 3H, 4-CH3), 3.37-3.72 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.59-4.75 (q, AB, 2H, 
JAB=16.8 Hz, CH2CO2CH2Ph), 5.20 (s, 2H, CO2CH2Ph), 7.25-7.47 (complex m, 10H, aromatic H); 13C NMR (100 MHz, 
CDCl3) δ 24.4 (3-CH3), 38.1 (4-CH3), 40.3 (CH2CO2CH2Ph), 55.1 (5-C), 67.5 (CO2CH2Ph), 68.0 (3-C), 126.1, 128.3, 
128.5, 128.6, 128.7, 129.0, 135.2, 140.7 (aromatic C), 167.8 (CO2CH2Ph), 170.4, 173.7 (2,6-C). Anal. Calcd for 
C21H22N2O4: C, 68.84; H, 6.05; N, 7.65; Found: C, 69.24; H, 6.43; N, 8.01. 
4.1.27. 4-Methyl-2,6-dioxo-3-phenyl-3-propyl-1-piperazineacetic acid benzyl ester 53 
Prepared from diketopiperazine 48 (1.15 g, 4.67 mmol) following the procedure described for compound 52. 
The crude oil was purified by column chromatography on silica gel with AcOEt-petroleum ether (44-60 °C) 1:6, 
as eluent, to afford the title compound 53 as a slightly off-yellow viscous oil (1.35 g, 75%): 1H NMR (400 MHz, 
CDCl3) δ 0.75 (t, 3H, J≃7.3 Hz, CH3(CH2)2), 1.04-1.15 (m, 2H, CH3CH2CH2), 1.78-2.09 (dm, 2H, CH3CH2CH2), 2.42 
(s, 3H, 4-CH3), 3.28-3.71 (q, AB, 2H, JAB=18.1 Hz, 5-H), 4.47-4.63 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.06-5.16 
(q, AB, 2H, JAB=12.3 Hz, CO2CH2Ph), 7.16-7.34 (complex m, 10H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.3 
(CH3(CH2)2), 16.3 (CH3CH2CH2), 37.8 (4-CH3), 39.0 (CH3CH2CH2), 40.4 (CH2CO2CH2Ph), 55.1 (5-C), 67.4 (CO2CH2Ph), 
70.3 (3-C), 127.0, 128.2, 128.4, 128.6, 128.7, 135.2, 136.9 (aromatic C), 167.8 (CO2CH2Ph), 170.4, 173.6 (2,6-C); 
HRMS (ESI): [M+H]+ calcd for C23H26N2O4, 395.1971, found 395.1967. 
 
4.1.28. 3-Butyl-4-methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid benzyl ester 54 
Prepared from diketopiperazine 49 (1.45 g, 5.57 mmol) following the procedure described for compound 52. 
The crude oil was purified by flash column chromatography eluting with AcOEt-n-hexane 1:3 to afford the title 
compound 54 as a colorless viscous oil (1.97 g, 87%): 1H NMR (600 MHz, CDCl3) δ 0.75 (t, 3H, J=7.2 Hz, CH3(CH2)3), 
1.04-1.20 (dm, 4H, CH3CH2CH2CH2), 1.85-2.09 (dm, 2H, CH3(CH2)2CH2), 2.42 (s, 3H, 4-CH3), 3.30-3.69 (q, AB, 2H, 
JAB=18.1 Hz, 5-H), 4.49-4.61 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2Ph), 5.08-5.14 (q, AB, 2H, JAB=12.2 Hz, CO2CH2Ph), 
7.16-7.32 (complex m, 10H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.0 (CH3(CH2)3), 22.9 (CH3CH2(CH2)2), 24.9 
(CH3CH2CH2CH2), 36.5 (CH3(CH2)2CH2), 37.8 (4-CH3), 40.4 (CH2CO2CH2Ph), 55.1 (5-C), 67.4 (CO2CH2Ph), 70.3 (3-C), 
127.0, 128.2, 128.4, 128.6, 128.7, 135.2, 136.8 (aromatic C), 167.8 (CO2CH2Ph), 170.4, 173.7 (2,6-C); HRMS (ESI): 
[M+H]+ calcd for C24H28N2O4, 409.2127, found 409.2118. 
4.1.29. 3-(4-Fluorophenyl)-3,4-dimethyl-2,6-dioxo-1-piperazineacetic acid benzyl ester 55 
Prepared from piperazine 50 (1.53 g, 6.48 mmol) following the procedure described for compound 52. The crude 
oil was purified by column chromatography on silica gel with AcOEt-n-hexane 1:2, as eluent, to afford the title 
compound 55 as a colorless viscous oil (1.78 g, 71%): 1H NMR (400 MHz, CDCl3) δ 1.62 (s, 3H, 3-CH3), 2.50 (s, 3H, 
4-CH3), 3.37-3.68 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.56-4.73 (q, AB, 2H, JAB=16.8 Hz, CH2CO2CH2Ph), 5.19 (s, 2H, 
CO2CH2Ph), 7.0 (t, 2H, J=8.7 Hz, 3,5-H for 4-FC6H4), 7.30-7.44 (complex m, 7H, C6H5, 2,6-H for 4-FC6H4); 13C NMR 
(50 MHz, CDCl3) δ 24.0 (3-CH3), 38.1 (4-CH3), 40.4 (CH2CO2CH2Ph), 54.9 (5-C), 67.5 (CO2CH2Ph), 69.1 (3-C), 115.6, 
116.0 (d, JC-F=21.3 Hz, 3,5-C for 4-FC6H4), 128.0, 128.1 (d, JC-F=7.9 Hz, 2,6-C for 4-FC6H4), 128.5, 128.7, 128.8 
(2,3,4,5,6-C for C6H5), 135.2, 136.5 (1-C for 4-FC6H4 and C6H5), 160.0, 164.9 (d, JC-F=246 Hz, 4-C for 4-FC6H4), 167.7 
(CO2CH2Ph), 170.1, 173.5 (2,6-C); HRMS (ESI): [M+H]+ calcd for C21H21FN2O4, 385.1564, found 385.1576. 
4.1.30. 3,4-Dimethyl-3-(4-nitrophenyl)-2,6-dioxo-1-piperazineacetic acid 4-methoxybenzyl ester 56 
Sodium hydride (92 mg, 3.83 mmol) was added in portions to a stirred solution of diketopiperazine 51 (840 mg, 
3.19 mmol) in dry DMF (20 mL), and the mixture was left stirring for 10 min at room temperature under argon. 
In this time window, the mixture color changed from light yellow to blue-red. Then, 4-methoxybenzyl 
bromoacetate (868 mg, 3.35 mmol) dissolved in dry DMF (5 mL) was added dropwise, and the mixture was 
stirred at room temperature for 48 h under argon. The reaction was then worked up in the same way described 
for the preparation of 52. The resulting orange thick oil was purified by column chromatography on silica gel 
eluting with AcOEt-n-hexane 1:3 and then 1:2 to afford the title compound 56 as a clear, yellow-orange viscous 
oil (1.18 g, 84%): 1H NMR (400 MHz, CDCl3) δ 1.65 (s, 3H, 3-CH3), 2.51 (s, 3H, 4-CH3), 3.40-3.64 (q, AB, 2H, JAB=18.1 
Hz, 5-H), 3.80 (s, 3H, OCH3), 4.55-4.69 (q, AB, 2H, JAB=16.7 Hz, CH2CO2CH2C6H4OCH3-4), 5.11 (s, 2H, 
CO2CH2C6H4OCH3-4), 6.88 (d, 2H, J=8.7 Hz, 3,5-H for 4-CH3OC6H4), 7.26 (d, 2H, J=8.7 Hz, 2,6-H for 4-CH3OC6H4), 
7.65 (d, 2H, J=9.0 Hz, 2,6-H for 4-NO2C6H4), 8.15 (d, 2H, J=9.0 Hz, 3,5-H for 4-NO2C6H4); 13C NMR (50 MHz, CDCl3) 
δ 23.5 (3-CH3), 38.1 (4-CH3), 40.4 (CH2CO2CH2C6H4OCH3-4), 54.7 (5-C), 55.3 (OCH3), 67.5 (3-C, CO2CH2C6H4OCH3-
4), 114.1, 124.1, 127.5, 130.3, 147.8, 148.0, 160.0 (aromatic C), 167.6 (CO2CH2C6H4OCH3-4), 169.4, 172.5 (2,6-
C); HRMS (ESI): [M+Na]+ calcd for C22H23N3O7, 464.1434, found 464.1424.  
4.1.31. 3,4-Dimethyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid 57 
Prepared from benzyl ester 52 (1.3 g, 3.55 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 156 mg) in abs EtOH 
(90 mL) as described for compound 33. The obtained white foamy solid strongly binds the hydrogenation 
solvent. Removal of the entrapped solvent as in 33 gave the title compound 57 as a glass solid (973 mg, almost 
quantitative yield): 1H NMR (400 MHz, CDCl3) δ 1.67 (s, 3H, 3-CH3), 2.57 (s, 3H, 4-CH3), 3.40-3.73 (q, AB, 2H, 
JAB=18.0 Hz, 5-H), 4.58-4.73 (q, AB, 2H, JAB≃17.0 Hz, CH2CO2H), 7.27-7.45 (m, 5H, aromatic H), 9.30-10.10 (br s, 
1H, CO2H); 13C NMR (100 MHz, CDCl3) δ 24.3 (3-CH3), 38.2 (4-CH3), 40.1 (CH2CO2H), 55.0 (5-C), 68.1 (3-C), 126.1, 
128.4, 129.0 (2,3,4,5,6-aromatic C), 140.4 (1-aromatic C), 170.3 (CO2H), 173.3, 173.6 (2,6-C); ESI+ MS: m/z 277.1 
[M+H]+. 
4.1.32. 4-Methyl-2,6-Dioxo-3-phenyl-3-propyl-1-piperazineacetic acid 58 
 
Prepared from benzyl ester 53 (2.6 g, 6.59 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 312 mg) in abs EtOH 
(165 mL) as described for compound 33. The obtained white foamy solid strongly binds the hydrogenation 
solvent. Removal of the entrapped solvent as in 33 gave the title compound 58 as an off-white gum (1.98 g, 
99%). The hydrochloride salt (58·HCl) was prepared by the same way described for 33·HCl, and obtained as a 
white solid (decomposed gradually above 85 °C): 1H NMR (400 MHz, DMSO-d6) δ 0.81 (t, 3H, J=7.3 Hz, CH3(CH2)2), 
1.03-1.28 (dm, 2H, CH3CH2CH2), 1.82-1.93 (m, 1H, CH3CH2CHH), 2.08-2.21 (m, 1H, CH3CH2CHH), 2.38 (s, 3H, 
+NHCH3), 3.32-3.61 (q, AB, 2H, JAB=18.2 Hz, 5-H), 3.66-4.35 (br s, 2H, +NHCH3, CO2H), 4.41 (s, 2H, CH2CO2H), 7.30-
7.43 (m, 5H, aromatic H); 13C NMR (50 MHz, DMSO-d6) δ 14.1 (CH3(CH2)2), 16.4 (CH3CH2CH2), 36.9 (+NHCH3), 37.5 
(CH3CH2CH2), 40.3 (CH2CO2H), 53.8 (5-C), 69.9 (3-C), 127.1, 128.1, 128.4 (2,3,4,5,6-aromatic C), 136.0 (1-aromatic 
C), 168.9 (CO2H), 169.3, 173.0 (2,6-C). Anal. Calcd for C16H21ClN2O4: C, 56.39; H, 6.21; N, 8.22; Found: C, 56.02; 
H, 5.99; N, 8.53. 
4.1.33. 3-Butyl-4-methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid 59 
Benzyl ester 54 (1.92 g, 4.7 mmol) was subjected to catalytic hydrogenolysis (H2/10% Pd-C, 230 mg) in abs EtOH 
(118 mL) as described in 33 to afford the title compound 59 as a glass solid (1.48 g, 99%): 1H NMR (600 MHz, 
CDCl3) δ 0.83 (t, 3H, J≃7.0 Hz, CH3(CH2)3), 1.06-1.14 (m, 1H, CH3CH2CHHCH2), 1.21-1.32 (m, 3H, CH3CH2CHHCH2), 
2.08-2.27 (dm, 2H, CH3(CH2)2CH2), 2.77 (s, 3H, 4-CH3), 3.70-3.89 (q, AB, 2H, JAB=17.9 Hz, 5-H), 4.66 (s, 2H, 
CH2CO2H), 5.20-7.20 (v br s, 1H, CO2H), 7.33-7.53 (m, 5H, aromatic H); 13C NMR (50 MHz, CDCl3) δ 13.9 
(CH3(CH2)3), 23.0 (CH3CH2(CH2)2), 25.6 (CH3CH2CH2CH2), 35.9 (CH3(CH2)2CH2), 38.3 (4-CH3), 40.6 (CH2CO2H), 54.2 
(5-C), 72.1 (3-C), 127.2, 129.3 (2,3,4,5,6-aromatic C), 134.4 (1-aromatic C), 167.4 (CO2H), 171.1, 171.6 (2,6-C); 
ESI+ MS: m/z 319.2 [M+H]+. 
4.1.34. 3-(4-Fluorophenyl)-3,4-dimethyl-2,6-dioxo-1-piperazineacetic acid 60 
Prepared from benzyl ester 55 (1.75 g, 4.55 mmol) by catalytic hydrogenolysis (H2/10% Pd-C, 210 mg) in abs 
EtOH (114 mL) as described for compound 33. The obtained white foamy solid strongly binds the hydrogenation 
solvent. Removal of the entrapped solvent as in 33 gave the title compound 60 as a glass solid (1.33 g, almost 
quantitative yield): 1H NMR (400 MHz, CDCl3) δ 1.66 (s, 3H, 3-CH3), 2.54 (s, 3H, 4-CH3), 3.44-3.70 (q, AB, 2H, 
JAB=18.1 Hz, 5-H), 4.58-4.73 (q, AB, 2H, JAB≃17.1 Hz, CH2CO2H), 7.05 (t, 2H, J≃8.6 Hz, 3,5-aromatic H), 7.38-7.48 
(q, 2H, J=5.2 Hz, 2,6-aromatic H), 9.98-10.22 (br s, 1H, CO2H); 13C NMR (50 MHz, CDCl3) δ 23.7 (3-CH3), 38.1 (4-
CH3), 40.1 (CH2CO2H), 54.7 (5-C), 67.5 (3-C), 115.6, 116.0 (d, JC-F=21.3 Hz, 3,5-aromatic C), 128.0, 128.2 (d, JC-
F=7.9 Hz, 2,6-aromatic C), 136.1 (1-aromatic C), 160.0, 164.9 (d, JC-F=246 Hz, 4-aromatic C), 170.1 (CO2H), 172.8, 
173.4 (2,6-C); ESI+ MS: m/z 295.3 [M+H]+. 
4.1.35. 2-Phenyl-2-propylaminopropanamide 66 
Acetophenone 18 (3.5 g, 29 mmol) was subjected to the Strecker reaction with n-propylamine hydrochloride 
(2.87 g, 30 mmol) and sodium cyanide (1.47 g, 30 mmol) following the procedure described for the preparation 
of compound 23. The obtained crude oily α-aminonitrile was then hydrated with H2SO4 97% (37 mL) as described 
in 23. The resulting crude thick oil was purified by column chromatography eluting with AcOEt-n-hexane 1:4 to 
1:0 to afford the title compound 66 as an off-yellow solid (2.7 g, 45% overall yield). An analytical sample was 
obtained as white crystals upon recrystallization of the product from Et2O-n-pentane. Mp 56-57 °C. 1H NMR (400 
MHz, CDCl3) δ 0.91 (t, 3H, J=7.4 Hz, HN(CH2)2CH3), 1.40-1.54 (m, 2H, HNCH2CH2CH3), 1.56-1.93 (v br s, 1H, 
HN(CH2)2CH3), 1.72 (s, 3H, CH3), 2.32-2.52 (sym m, 2H, HNCH2CH2CH3), 6.50 (br s, 1H, CONHH), 7.01 (br s, 1H, 
CONHH), 7.20-7.37 (m, 3H, aromatic H), 7.51 (d, 2H, J=7.2 Hz, aromatic H); 13C NMR (50 MHz, CDCl3) δ 11.8 
(HN(CH2)2CH3), 22.6 (CH3), 24.0 (HNCH2CH2CH3), 45.3 (HNCH2CH2CH3), 64.8 (Ph(CH3)CNH), 126.2, 127.4, 128.5 
(2,3,4,5,6-aromatic C), 143.0 (1-aromatic C), 178.3 (CONH2). Anal. Calcd for C12H18N2O: C, 69.87; H, 8.80; N, 
13.58; Found: C, 70.14; H, 9.12; N, 13.61. 
4.1.36. 2-Butylamino-2-phenylpropanamide 67 
Acetophenone 18 (3.5 g, 29 mmol) was subjected to the Strecker reaction with n-butylamine hydrochloride 
(3.29 g, 30 mmol) and sodium cyanide (1.47 g, 30 mmol) following the procedure described for the preparation 
 
of compound 23. The crude oily α-aminonitrile obtained was then hydrated with H2SO4 97% (37 mL). The 
resulting crude thick oil was purified by column chromatography eluting with AcOEt-n-hexane 1:3 to 1:0 to 
afford the title compound 67 as a white crystalline solid (3 g, 47% overall yield): mp 83-85 °C (Et2O-n-pentane); 
1H NMR (400 MHz, CDCl3) δ 0.89 (t, 3H, J=7.2 Hz, HN(CH2)3CH3), 1.10-1.62 (v br s, 1H, HN(CH2)3CH3), 1.27-1.50 
(dm, 4H, HNCH2CH2CH2CH3), 1.72 (s, 3H, CH3), 2.36-2.53 (sym m, 2H, HNCH2(CH2)2CH3), 6.33 (s, 1H, CONHH), 
7.01 (s, 1H, CONHH), 7.20-7.38 (m, 3H, aromatic H), 7.51 (d, 2H, J=7.2 Hz, aromatic H); 13C NMR (50 MHz, CDCl3) 
δ 14.1 (HN(CH2)3CH3), 20.5 (HN(CH2)2CH2CH3), 22.6 (CH3), 33.1 (HNCH2CH2CH2CH3), 43.2 (HNCH2(CH2)2CH3), 64.9 
(Ph(CH3)CNH), 126.2, 127.4, 128.5 (2,3,4,5,6-aromatic C), 143.1 (1-aromatic C), 178.3 (CONH2). Anal. Calcd for 
C13H20N2O: C, 70.87; H, 9.15; N, 12.72; Found: C, 71.04; H, 9.31; N, 12.52. 
4.1.37. N-[(1-Aminocarbonyl-1-phenyl)ethyl]-N-propylglycine ethyl ester 68 
Sodium bicarbonate (336 mg, 4 mmol) and ethyl bromoacetate (731 mg, 4.38 mmol) were added successively 
to a solution of the aminoamide derivative 66 (765 mg, 3.71 mmol) in dry DMF (46 mL), and the resulting mixture 
was heated at 40-43 °C for 6 days with stirring. The reaction mixture was then poured into ice-water (40 mL) 
and extracted with AcOEt (3 × 40 mL). The combined organic phase was washed once with brine (40 mL), dried 
(Na2SO4) and concentrated to dryness under reduced pressure. The remaining oily residue was 
chromatographed on silica gel column with AcOEt-n-hexane 1:2, as eluent, to afford the title compound 68 as a 
white crystalline solid (615 mg, 57%): mp 105-106 °C (Et2O-n-pentane); 1H NMR (400 MHz, CDCl3) δ 0.80 (t, 3H, 
J≃7.4 Hz, N(CH2)2CH3), 1.26 (t, 3H, J=7.2 Hz, CO2CH2CH3), 1.29-1.48 (m, 2H, NCH2CH2CH3), 1.65 (s, 3H, CH3), 2.23-
2.50 (dm, 2H, NCH2CH2CH3), 3.10-3.40 (q, AB, 2H, JAB≃17.4 Hz, NCH2CO2CH2CH3), 4.11-4.22 (qd, 2H, J1≃1.8 Hz, 
J2≃7.0 Hz, CO2CH2CH3), 5.60 (s, 1H, CONHH), 7.21-7.36 (m, 3H, aromatic H), 7.63 (d, 2H, J=7.6 Hz, aromatic H), 
7.82 (s, 1H, CONHH); 13C NMR (50 MHz, CDCl3) δ 11.8 (NCH2CH2CH3), 14.2 (CO2CH2CH3) 14.8 (CH3), 22.1 
(NCH2CH2CH3), 55.0 (NCH2CO2CH2CH3), 55.5 (NCH2CH2CH3), 61.2 (CO2CH2CH3), 72.4 (Ph(CH3)CNH), 127.2, 127.7, 
128.5 (2,3,4,5,6-aromatic C), 141.7 (1-aromatic C), 173.5 (CO2CH2CH3), 176.8 (CONH2). Anal. Calcd for 
C16H24N2O3: C, 65.73; H, 8.27; N, 9.58; Found: C, 65.92; H, 8.65; N, 9.54. 
4.1.38. N-[(1-Aminocarbonyl-1-phenyl)ethyl]-N-butylglycine ethyl ester 69 
Prepared from the aminoamide derivative 67 (881 mg, 4 mmol) by the same procedure described for compound 
68. The resulting crude thick oil was chromatographed on silica gel column with AcOEt-n-hexane 1:3, as eluent, 
to afford the title compound 69 as a white solid (573 mg, 47%): mp 108-110 °C (Et2O-n-pentane); 1H NMR (400 
MHz, CDCl3) δ 0.80 (t, 3H, J=7.2 Hz, N(CH2)3CH3), 1.08-1.46 (m, 4H, NCH2CH2CH2CH3), 1.27 (t, 3H, J≃7.0 Hz, 
CO2CH2CH3), 1.64 (s, 3H, CH3), 2.27-2.35 (m, 1H, NCHH(CH2)2CH3), 2.42-2.55 (m, 1H, NCHH(CH2)2CH3), 3.08-3.39 
(q, AB, 2H, JAB=17.2 Hz, NCH2CO2CH2CH3), 4.08-4.26 (sym m, 2H, CO2CH2CH3), 5.64 (br s, 1H, CONHH), 7.20-7.38 
(m, 3H, aromatic H), 7.63 (d, 2H, J=8.0 Hz, aromatic H), 7.82 (s, 1H, CONHH); 13C NMR (50 MHz, CDCl3) δ 14.1 
(N(CH2)3CH3), 14.2 (CO2CH2CH3), 14.8 (CH3), 20.5 (N(CH2)2CH2CH3), 31.2 (NCH2CH2CH2CH3) 53.3 (NCH2(CH2)2CH3), 
55.0 (NCH2CO2CH2CH3), 61.1 (CO2CH2CH3), 72.4 (Ph(CH3)CNH), 127.2, 127.6, 128.4 (2,3,4,5,6-aromatic C), 141.8 
(1-aromatic C), 173.6 (CO2CH2CH3), 176.9 (CONH2). Anal. Calcd for C17H26N2O3: C, 66.64; H, 8.55; N, 9.14; Found: 
C, 66.95; H, 8.81; N, 8.92. 
4.1.39. 3-Methyl-2,6-dioxo-3-phenyl-4-propyl-1-piperazineacetic acid benzyl ester 70 
The amide-ester derivative 68 (710 mg, 2.43 mmol) was converted to the title benzyl ester 70 following the 
procedure described for the preparation of compound 28. Purification of the crude product (yellowish oil) by 
column chromatography on silica gel (AcOEt-n-hexane 1:5) gave 850 mg (89%) of colourless viscous oil. 1H NMR 
(400 MHz, CDCl3) δ 0.82 (t, 3H, J≃7.4 Hz, N(CH2)2CH3), 1.32-1.48 (m, 2H, NCH2CH2CH3), 1.56 (s, 3H, 3-CH3), 2.38-
2.49 (m, 1H, NCHHCH2CH3), 2.55-2.65 (m, 1H, NCHHCH2CH3), 3.40-3.57 (q, AB, 2H, JAB≃18.2 Hz, 5-H), 4.47-4.65 
(q, AB, 2H, JAB=16.8 Hz, CH2CO2CH2Ph), 5.10 (s, 2H, CO2CH2Ph), 7.15-7.40 (complex m, 10H, aromatic H); 13C NMR 
(50 MHz, CDCl3) δ 11.6 (N(CH2)2CH3), 21.5 (NCH2CH2CH3), 23.5 (3-CH3), 40.4 (CH2CO2CH2Ph), 50.5 (NCH2CH2CH3), 
51.1 (5-C), 67.4 (CO2CH2Ph), 68.0 (3-C), 126.2, 128.1, 128.4, 128.6, 128.7, 128.9, 129.3, 129.4, 135.2, 141.4 
 
(aromatic C), 167.7 (CO2CH2Ph), 170.8, 173.9 (2,6-C); HRMS (ESI): [M+H]+ calcd for C23H26N2O4, 395.1971, found 
395.1968. 
4.1.40. 4-Butyl-3-methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid benzyl ester 71 
The amide-ester derivative 69 (560 mg, 1.83 mmol) was converted to the title benzyl ester 71 following the 
procedure described for the preparation of compound 28. Purification of the crude product (off-yellow thick oil) 
by column chromatography on silica gel (AcOEt-n-hexane 1:6) gave 606 mg (81%) of colourless viscous oil. 1H 
NMR (400 MHz, CDCl3) δ 0.90 (t, 3H, J=7.2 Hz, N(CH2)3CH3), 1.21-1.53 (complex m, 4H, NCH2CH2CH2CH3), 1.65 (s, 
3H, 3-CH3), 2.46-2.58 (m, 1H, NCHH(CH2)2CH3), 2.68-2.81 (m, 1H, NCHH(CH2)2CH3), 3.48-3.68 (q, AB, 2H, JAB=18.0 
Hz, 5-H), 4.53-4.76 (q, AB, 2H, JAB=16.8 Hz, CH2CO2CH2Ph), 5.19 (s, 2H, CO2CH2Ph), 7.20-7.50 (complex m, 10H, 
aromatic H); 13C NMR (50 MHz, CDCl3) δ 14.0 (N(CH2)3CH3), 20.2 (N(CH2)2CH2CH3), 23.5 (3-CH3), 30.5 
(NCH2CH2CH2CH3), 40.5 (CH2CO2CH2Ph), 48.4 (NCH2(CH2)2CH3), 51.1 (5-C), 67.4 (CO2CH2Ph), 68.0 (3-C), 126.2, 
128.2, 128.4, 128.6, 128.7, 128.9, 135.3, 141.4 (aromatic C), 167.7 (CO2CH2Ph), 170.8, 173.9 (2,6-C); HRMS (ESI): 
[M+H]+ calcd for C24H28N2O4, 409.2127, found 409.2150. 
4.1.41. 3-Methyl-2,6-dioxo-3-phenyl-4-propyl-1-piperazineacetic acid 72 
Benzyl ester 70 (1.25 g, 3.17 mmol) was subjected to catalytic hydrogenolysis (H2/10% Pd-C, 150 mg) in abs EtOH 
(143 mL) as described in 33 to give a colourless glass solid. Trituration of this product material with Et2O gave 
the title compound 72 as a white crystalline solid (900 mg, 93%). A recrystallized sample had mp 152-154 °C 
(from Et2O). 1H NMR (400 MHz, CDCl3) δ 0.92 (t, 3H, J=7.2 Hz, N(CH2)2CH3), 1.44-1.60 (sym m, 2H, NCH2CH2CH3), 
1.66 (s, 3H, 3-CH3), 2.49-2.63 (m, 1H, NCHHCH2CH3), 2.68-2.80 (m, 1H, NCHHCH2CH3), 3.47-3.70 (q, AB, 2H, 
JAB=18.4 Hz, 5-H), 4.53-4.73 (q, AB, 2H, JAB≃17.0 Hz, CH2CO2H), 7.20-7.50 (complex m, 5H, aromatic H), 9.61-
10.53 (br s, 1H, CO2H); 13C NMR (50 MHz, CDCl3) δ 11.6 (N(CH2)2CH3), 21.5 (NCH2CH2CH3), 23.6 (3-CH3), 40.1 
(CH2CO2H), 50.7 (NCH2CH2CH3), 51.1 (5-C), 68.0 (3-C), 126.2, 128.2, 128.9 (2,3,4,5,6-aromatic C), 141.3 (1-
aromatic C), 170.8 (CO2H), 173.5, 173.9 (2,6-C). Anal. Calcd for C16H20N2O4: C, 63.14; H, 6.62; N, 9.21; Found: C, 
63.43; H, 6.72; N, 9.52. 
4.1.42. 4-Butyl-3-methyl-2,6-dioxo-3-phenyl-1-piperazineacetic acid 73 
Benzyl ester 71 (600 mg, 1.47 mmol) was subjected to catalytic hydrogenolysis (H2/10% Pd-C, 72 mg) in abs EtOH 
(66 mL) as described in 33 to give a colourless glass solid. Trituration of this product material with a diethyl 
ether-n-pentane 1:1 mixture afforded the title compound 73 as a white crystalline solid (460 mg, 98%). A 
specimen was recrystallized from Et2O-n-pentane to give an analytical sample which had mp 102-103 °C. 1H NMR 
(400 MHz, CDCl3) δ 0.91 (t, 3H, J=7.2 Hz, N(CH2)3CH3), 1.25-1.57 (complex m, 4H, NCH2CH2CH2CH3), 1.67 (s, 3H, 
3-CH3), 2.50-2.63 (m, 1H, NCHH(CH2)2CH3), 2.75-2.85 (m, 1H, NCHH(CH2)2CH3), 3.51-3.68 (q, AB, 2H, JAB=18.0 Hz, 
5-H), 4.53-4.72 (q, AB, 2H, JAB≃17.0 Hz, CH2CO2H), 7.26-7.48 (m, 5H, aromatic H), 9.80-11.1 (v br s, 1H, CO2H); 
13C NMR (50 MHz, CDCl3) δ 14.0 (N(CH2)3CH3), 20.3 (N(CH2)2CH2CH3), 23.6 (3-CH3), 30.4 (NCH2CH2CH2CH3), 40.1 
(CH2CO2H), 48.6 (NCH2(CH2)2CH3), 51.1 (5-C), 68.1 (3-C), 126.2, 128.2, 128.9 (2,3,4,5,6-aromatic C), 141.3 (1-
aromatic C), 170.8 (CO2H), 173.6, 173.9 (2,6-C); Anal. Calcd for C17H22N2O4: C, 64.13; H, 6.97; N, 8.80; Found: C, 
63.82; H, 7.12; N, 9.03. 
4.1.43. N-Hydroxy-3-methyl-2,6-dioxo-3-phenyl-1-piperazineacetamide 6 
1,1'-Carbonyldiimidazol (409 mg, 2.52 mmol) was added to a solution of carboxylic acid 33 (550 mg, 2.1 mmol) 
in dry THF (42 mL), and the mixture was allowed to stir at 28 °C for 1 h under argon. Then, O-
benzylhydroxylamine hydrochloride (402 mg, 2.52 mmol) was added followed by triethylamine (510 mg, 5.04 
mmol). After the mixture was stirred for 24 h at 28 °C and 1 h at 45 °C under argon, the solvent was evaporated 
under reduced pressure. Water (50 mL) was added to the residue, and the mixture was extracted with ethyl 
acetate (3 × 50 mL). The combined organic phase was washed with brine (2 × 50 mL), dried (Na2SO4) and 
evaporated to dryness in vacuo. The viscous oily residue was purified by column chromatography on silica gel 
with AcOEt-n-hexane 2:1, as eluent, to afford the N-benzyloxy precursor 37 as a white foamy solid, which 
strongly binds the elution solvents. Removal of the entrapped solvents upon drying at 62-64 °C under high 
 
vacuum (10-2 mmHg) in an Abderhalden apparatus gave 37 as a glass solid (572 mg, 74%). This compound 
appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR (600 MHz, CDCl3, 
283 K) δ 1.59, 1.63 (s + s, 3H, CH3), 2.26-2.74 (br s, 1H, 4-H), 3.36-3.50 (q, 1H, J=18.5 Hz, 5-H), 3.59-3.71 (q, 1H, 
J=18.5 Hz, 5-H), 4.30-4.43 (q, AB, 1.14H, JAB≃15.1 Hz, CH2CONHOCH2Ph), 4.70 (s, 0.94H, CH2CONHOCH2Ph), 4.87, 
4.91 (s + s, 2H, CONHOCH2Ph), 7.28-7.50 (complex m, 10H, aromatic H), 8.59 (s, 0.48H, CONHOCH2Ph), 9.37 (s, 
0.57H, CONHOCH2Ph); 13C NMR (150 MHz, CDCl3, 283 K) δ 28.7 (CH3), 39.4 (CH2CONHOCH2Ph), 45.9 (5-C), 62.5 
(3-C), 78.2, 79.5 (CONHOCH2Ph), 125.6, 125.7, 128.1, 128.5, 128.7, 128.8, 128.9, 129.1, 129.3, 129.4, 134.0, 
134.9, 138.7 (aromatic C), 165.2, 170.3 (CONHOCH2Ph), 171.8, 173.8 (2,6-C); ESI+MS: m/z 368.2 [M+H]+. 
A solution of O-benzyl hydroxamate 37 (570 mg, 1.55 mmol) in abs EtOH (70 mL) was hydrogenated over 10% 
Pd-C (68 mg) at room temperature under 50 psi of hydrogen. After 3 h the catalyst was filtered off, washed with 
EtOH (3 × 15 mL), and the combined filtrates were evaporated to dryness under reduced pressure. The residual 
material (off-white foamy solid) was chromatographed on silica gel column with AcOEt-MeOH 15:1, as eluent, 
to afford the title compound 6 as a white foamy solid, which strongly binds the aforementioned solvents. 
Removal of the entrapped solvents upon drying at 62-64 °C under high vacuum (10-2 mmHg) in an Abderhalden 
apparatus gave 6 as a slightly off-yellow crystalline solid (350 mg, 81%): mp 80-83 °C (dec); 1H NMR (400 MHz, 
DMSO-d6) δ 1.51 (s, 3H, CH3), 3.07-3.19 (q, 1H, J=10.7 Hz, 5-H), 3.53-3.64 (dd, 1H, J=4.1, 18.3 Hz, 5-H), 3.79-3.90 
(dd, 1H, J=4.0, 10.6 Hz, 4-H), 4.19-4.32 (q, AB, 1.5H, JAB=15.6 Hz, CH2CONHOH, E-isomer), 4.49-4.61 (q, AB, 0.46H, 
JAB≈17.4 Hz, CH2CONHOH, Z-isomer), 7.27-7.52 (complex m, 5H, aromatic H), 8.93 (s, 0.74H, CONHOH, E-isomer), 
9.34 (s, 0.2H, CONHOH, Z-isomer), 10.21 (s, 0.2H, CONHOH, Z-isomer), 10.65 (s, 0.75H, CONHOH, E-isomer); 13C 
NMR (100 MHz, DMSO-d6) δ 28.2 (CH3), 39.0 (CH2CONHOH, E-isomer), 39.4 (CH2CONHOH, Z-isomer), 45.8 (5-C), 
62.1 (3-C), 126.0, 126.4, 126.6, 127.7, 128.1, 128.5, 128.6 (2,3,4,5,6-aromatic C), 140.2, 140.3 (1-aromatic C), 
163.9 (CONHOH, E-isomer), 169.3 (CONHOH, Z-isomer), 171.5, 173.7, 173.8 (2,6-C); HRMS (APCI+): [M+H]+ calcd 
for C13H15N3O4, 278.1135, found 278.1136. The hydrochloride salt (6·HCl) was prepared by treating a solution of 
6 in AcOEt-Et2O 2:3 with saturated solution of HCl in Et2O under ice cooling. The solvents were then evaporated 
under reduced pressure, and the white solid was triturated with Et2O, filtered and dried in vacuo. Mp 141-145 
°C (dec) (slightly hygroscopic). Anal. Calcd for C13H16ClN3O4: C, 49.77; H, 5.14; N, 13.39; Found: C, 49.38; H, 5.52; 
N, 13.03. 
4.1.44. N-Hydroxy-2,6-dioxo-3-phenyl-3-propyl-1-piperazineacetamide 7 
The N-benzyloxy precursor 38 was prepared from carboxylic acid 34 (700 mg, 2.41 mmol) following the 
procedure described for the preparation of compound 37 (precursor for 6). The crude viscous oil was purified 
by column chromatography on silica gel with AcOEt-n-hexane 2:3, as eluent, to afford 38 as a glass solid (675 
mg, 71%). This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 
1H NMR (400 MHz, CDCl3) δ 0.75 (t, 3H, J=7.2 Hz, CH3(CH2)2), 1.10-1.28 (m, 2H, CH3CH2CH2), 1.72-2.02 (dm, 2H, 
CH3CH2CH2), 2.43 (s, 1H, 4-H), 3.28-3.69 (dm, 2H, 5-H), 4.14-4.39 (m, 1H, CH2CONHOCH2Ph), 4.60, 4.65 (s + s, 
0.95H, CH2CONHOCH2Ph), 4.78 (s, 2H, CONHOCH2Ph), 7.10-7.45 (m, 10H, aromatic H), 8.71 (s, 0.3H, 
CONHOCH2Ph), 9.46 (s, 0.4H, CONHOCH2Ph); 13C NMR (50 MHz, CDCl3) δ 14.3 (CH3(CH2)2), 17.2 (CH3CH2CH2), 
39.5 (CH2CONHOCH2Ph), 43.9 (CH3CH2CH2), 45.9 (5-C), 65.7 (3-C), 78.6, 79.5 (CONHOCH2Ph), 126.2, 128.1, 128.7, 
128.8, 129.3, 135.1, 137.8 (aromatic C), 165.4, 170.5 (CONHOCH2Ph), 171.8, 173.4 (2,6-C); EI MS: m/z 396.2 
([M+H]+, 9), 395.1 ([M]+, 27), 352.1 ([M-CH2CH2CH3]+, 25), 305.1 ([M+H-CH2Ph]+, 11), 304.0 ([M-CH2Ph]+, 67), 
217.0 (73), 160.0 (83), 90.9 (100).   
Compound 38 (1.2 g, 3.03 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 144 mg), in abs EtOH 
(136 mL) as described for the preparation of compound 6 from 37. The hydrogenation product (off-white foamy 
solid) was chromatographed on silica gel column eluting first with AcOEt-n-hexane 1:2 and then AcOEt to afford 
the title compound 7 as a white foamy solid. This material gave white crystals upon dissolving in Et2O (15 mL) 
and subsequent evaporation of the solvent twice. (700 mg, 76%): mp 148-150 °C (dec) (MeOH-Et2O); 1H NMR 
(400 MHz, DMSO-d6) δ 0.78 (t, 3H, J=6.3, 7.4 Hz, CH3(CH2)2), 1.12-1.36 (m, 2H, CH3CH2CH2), 1.70-1.81 (td, 1H, 
 
J≈4.5 Hz, J=11.9, 13.4 Hz, CH3CH2CHH), 1.82-1.93 (td, 1H, J=2.6-4.0 Hz, J=11.9, 13.1 Hz, CH3CH2CHH), 3.16-3.27 
(q, 1H, J=10.1 Hz, 5-H), 3.56-3.66 (dd, 1H, J=3.7, 18.1 Hz, 5-H), 3.69-3.78 (dd, 1H, J≃2.8, 9.8 Hz, 4-H), 4.15-4.30 
(q, AB, 1.53H, JAB=15.5 Hz, CH2CONHOH, E-isomer), 4.45-4.59 (q, AB, 0.41H, JAB=16.8 Hz, CH2CONHOH, Z-isomer), 
7.25-7.51 (m, 5H, aromatic H), 8.92 (s, 0.7H, CONHOH, E-isomer), 9.33 (s, 0.2H, CONHOH, Z-isomer), 10.20 (s, 
0.2H, CONHOH, Z-isomer), 10.63 (s, 0.7H, CONHOH, E-isomer); 13C NMR (50 MHz, DMSO-d6) δ 14.2 (CH3(CH2)2), 
16.7 (CH3CH2CH2), 38.9 (CH2CONHOH), 43.4 (CH3CH2CH2), 45.7 (5-C), 65.0 (3-C), 126.2, 127.6, 128.5 (2,3,4,5,6-
aromatic C), 138.7 (1-aromatic C), 163.8 (CONHOH, E-isomer), 169.2 (CONHOH, Z-isomer), 171.3, 173.1 (2,6-C); 
ESI+ MS: m/z 306.5 [M+H]. Anal. Calcd for C15H19N3O4: C, 59.01; H, 6.27; N, 13.76; Found: C, 58.87; H, 6.30; N, 
13.92. The hydrochloride salt (7·HCl) was prepared by treating a solution of 7 in MeOH-Et2O 1:15 with saturated 
solution of HCl in Et2O under ice cooling, and was fully precipitated by adding Et2O. The white solid was collected 
by vacuum filtration, triturated with Et2O, and dried in vacuo (decomposed gradually above 115 °C). Anal. Calcd 
for C15H20ClN3O4 · 0.15 Et2O: C, 53.09; H, 6.14; N, 11.90; Found: C, 52.80; H, 6.21; N, 11.62. 
4.1.45. 3-Butyl-N-hydroxy-2,6-dioxo-3-phenyl-1-piperazineacetamide 8 
The N-benzyloxy precursor 39 was prepared from carboxylic acid 35 (1 g, 3.29 mmol) following the procedure 
described for the preparation of compound 37 (precursor for 6). The crude oil was purified by flash column 
chromatography eluting with AcOEt-n-hexane 1:1 to afford 39 as an off-yellow glass oil (870 mg, 64%). This 
compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR (600 
MHz, CDCl3) δ 0.77 (t, 3H, J=5.6 Hz, CH3(CH2)3), 1.06-1.30 (m, 4H, CH3CH2CH2CH2), 1.75-2.06 (dm, 2H, 
CH3(CH2)2CH2), 2.27-2.49 (br s, 1H, 4-H), 3.44 (d, 1H, J=17.0 Hz, 5-H), 3.62 (d, 1H, J=18.2 Hz, 5-H), 4.28 (br d, 
0.76H, J=26.8 Hz, CH2CONHOCH2Ph), 4.63, 4.68 (s + s, 1.47H, CH2CONHOCH2Ph), 4.83 (s, 2H, CONHOCH2Ph), 
7.16-7.44 (complex m, 10H, aromatic H), 8.32 (s, 0.26H, CONHOCH2Ph), 8.87 (s, 0.23H, CONHOCH2Ph); 13C NMR 
(50 MHz, CDCl3) δ 13.9 (CH3(CH2)3), 22.9 (CH3CH2(CH2)2), 25.9 (CH3CH2CH2CH2), 39.5 (CH2CONHOCH2Ph), 41.6 
(CH3(CH2)2CH2), 46.0 (5-C), 65.7 (3-C), 78.4, 79.6 (CONHOCH2Ph), 126.3, 128.2, 128.8, 128.9, 129.3, 129.4, 135.1, 
137.9 (aromatic C), 160.0 (CONHOCH2Ph), 171.7, 173.4 (2,6-C); EI MS: m/z 410.1 ([M+H]+, 17), 409.1 ([M]+, 55), 
352.1 ([M-(CH2)3CH3]+, 59), 318.1 ([M-CH2Ph]+, 100), 302.1 ([M-OCH2Ph]+, 47).   
Compound 39 (900 mg, 2.2 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 108 mg) in abs EtOH 
(98 mL) as described for the preparation of compound 6 from 37. The crude hydrogenation product (glass oil) 
was chromatographed on silica gel column with AcOEt, as eluent, to afford the title compound 8 as a white 
crystalline solid (530 mg, 75%): mp 158-160 °C (dec) (MeOH-Et2O); 1H NMR (600 MHz, DMSO-d6) δ 0.80 (t, 3H, 
J=7.0 Hz, CH3(CH2)3), 1.12-1.29 (complex m, 4H, CH3CH2CH2CH2), 1.75-1.95 (dm, 2H, CH3(CH2)2CH2), 3.18-3.26 (q, 
1H, J=10.0 Hz, 4-H), 3.58-3.64 (dd, 1H, J=4.1, 18.0 Hz, 5-H), 3.69-3.75 (dd, 1H, J=4.1, 10.1 Hz, 5-H), 4.17-4.28 (q, 
AB, 1.6H, JAB=15.5 Hz, CH2CONHOH, E-isomer), 4.47-4.57 (q, AB, 0.4H, JAB=16.7 Hz, CH2CONHOH, Z-isomer), 7.28-
7.48 (m, 5H, aromatic H), 8.89 (s, 0.7H, CONHOH, E-isomer), 9.30 (s, 0.2H, CONHOH, Z-isomer), 10.17 (s, 0.2H, 
CONHOH, Z-isomer), 10.60 (s, 0.7H, CONHOH, E-isomer); 13C NMR (50 MHz, DMSO-d6) δ 13.9 (CH3(CH2)3), 22.4 
(CH3CH2(CH2)2), 25.5 (CH3CH2CH2CH2), 38.9 (CH2CONHOCH2Ph), 41.0 (CH3(CH2)2CH2), 45.7 (5-C), 65.0 (3-C), 126.2, 
127.6, 128.5 (2,3,4,5,6-aromatic C), 138.8 (1-aromatic C), 163.8 (CONHOH, E-isomer), 169.2 (CONHOH, Z-
isomer), 171.3, 173.1 (2,6-C); ESI+ MS: m/z 342.3 [M+Na]+. Anal. Calcd for C16H21N3O4: C, 60.17; H, 6.63; N, 13.16; 
Found: C, 60.25; H, 6.70; N, 12.98. The hydrochloride salt (8·HCl) was prepared as described for 7·HCl 
(decomposed gradually above 100 °C). Anal. Calcd for C16H22ClN3O4: C, 54.01; H, 6.23; N, 11.81; Found: C, 53.63; 
H, 5.92; N, 11.54. 
4.1.46. 3-(4-Fluorophenyl)-N-hydroxy-3-methyl-2,6-dioxo-1-piperazineacetamide 9 
A stirred solution of carboxylic acid 36 (750 mg, 2.68 mmol) and 1,1'-carbonyldiimidazol (522 mg, 3.22 mmol) in 
dry THF (53 mL) was heated at 55 °C for 1 h under argon. Then, O-benzylhydroxylamine hydrochloride (514 mg, 
3.22 mmol) was added followed by triethylamine (652 mg, 6.44 mmol), and the mixture was stirred at 55 °C for 
25 h under argon. The reaction was then worked up in the same way described in 37. The resulting oily residue 
was purified by column chromatography eluting first with AcOEt-n-hexane 1:2 and then 1:1 to afford the 
 
corresponding N-benzyloxy precursor 40 as a white foamy solid, which strongly binds the elution solvents. 
Removal of the entrapped solvents as in 37 gave 40 as a glass solid (632 mg, 61%): This compound appears in 
the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR (400 MHz, CDCl3) δ 1.57 (s, 
3H, CH3), 2.36-2.62 (br s, 1H, 4-H), 3.38 (t, 1H, J≃18.4 Hz, 5-H), 3.64 (t like, 1H, J=16.4, 17.8 Hz, 5-H), 4.23-4.44 
(q, AB, 1H, JAB≃14.8 Hz, CH2CONHOCH2Ph), 4.68 (s, 0.94H, CH2CONHOCH2Ph), 4.86, 4.90 (s + s, 2H, 
CONHOCH2Ph), 7.04 (t, 2H, J=8.4 Hz, 3,5-H for 4-FC6H4), 7.15-7.55 (complex m, 7H, C6H5, 2,6-H for 4-FC6H4), 8.60 
(br s, 0.4H, CONHOCH2Ph), 9.30 (br s, 0.5H, CONHOCH2Ph); 13C NMR (50 MHz, CDCl3) δ 29.0 (CH3), 39.6 
(CH2CONHOCH2Ph), 46.0 (5-C), 62.3 (3-C), 78.5, 79.7 (CONHOCH2Ph), 115.7, 116.1 (d, JC-F=21.3 Hz, 3,5-C for 4-
FC6H4), 127.7, 127.9 (d, JC-F=8.1 Hz, 2,6-C for 4-FC6H4), 128.8, 129.4 (2,3,4,5,6-C for C6H5), 134.7, 134.8 (1-C for 
4-FC6H4 and C6H5), 160.1, 165.0 (d, JC-F=246 Hz, 4-C for 4-FC6H4), 165.4, 170.5 (CONHOCH2Ph, weak signal 
intensities), 171.7, 173.8 (2,6-C); ESI+ MS: m/z 386.3 [M+H]+. 
Compound 40 (1 g, 2.59 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 120 mg), in abs EtOH 
(117 mL) as described for the preparation of compound 6 from 37. The crude hydrogenation product (off-white 
foamy solid) was chromatographed on silica gel column with AcOEt, as eluent, to afford the title compound 9 
as a white foamy solid, which gave white crystals upon trituration with Et2O (720 mg, 94%): mp 154-158 °C (dec) 
(AcOEt-Et2O); 1H NMR (400 MHz, DMSO-d6) δ 1.49 (s, 3H, CH3), 3.02-3.19 (q, 1H, J=10.7 Hz, 5-H), 3.52-3.65 (dd, 
1H, J=3.9, 18.3 Hz, 5-H), 3.80-3.95 (dd, 1H, J≃3.8, 10.5 Hz, 4-H), 4.24 (s, 1.5H, CH2CONHOH, E-isomer), 4.54 (s, 
0.5H, CH2CONHOH, Z-isomer), 7.19 (t, 2H, J=8.7 Hz, 3,5-aromatic H), 7.51 (t like, 2H, J=5.6, 8.1 Hz, 2,6-aromatic 
H), 8.96 (s, 0.8H, CONHOH, E-isomer), 9.37 (s, 0.2H, CONHOH, Z-isomer), 10.25 (s, 0.2H, CONHOH, Z-isomer), 
10.67 (s, 0.8H, CONHOH, E-isomer); 13C NMR (50 MHz, DMSO-d6) δ 28.3 (CH3), 39.0 (CH2CONHOH, E-isomer), 
39.5 (CH2CONHOH, Z-isomer), 45.6 (5-C), 61.7 (3-C), 115.2, 115.6 (d, JC-F=21.1 Hz, 3,5-aromatic C), 128.2, 128.3 
(d, JC-F=7.5 Hz, 2,6-aromatic C), 136.4 (1-aromatic C), 159.2, 164.0 (d, JC-F=242 Hz, 4-aromatic C), 163.9 (CONHOH, 
E-isomer), 169.2 (CONHOH, Z-isomer), 171.4, 173.6 (2,6-C); Anal. Calcd for C13H14FN3O4: C, 52.88; H, 4.78; N, 
14.23; Found: C, 52.67; H, 4.88; N, 14.32. The hydrochloride salt was prepared by treating an ethyl acetate 
solution of 9 with saturated solution of HCl in Et2O under ice cooling. The white precipitate was collected by 
vacuum filtration, triturated with Et2O and dried (decomposed gradually above 120 °C). Anal. Calcd for 
C13H15ClFN3O4: C, 47.07; H, 4.56; N, 12.67; Found: C, 46.70; H, 4.48; N, 12.35. 
4.1.47. N-Hydroxy-3-methyl-3-(4-nitrophenyl)-2,6-dioxo-1-piperazineacetamide Hydrochloride 10 
4-Methoxybenzyl ester 32 (1 g, 2.34 mmol) was taken in CH2Cl2 (26 mL) and treated with trifluoroacetic acid (4 
mL). The mixture was left stirring at room temperature for 90 min, evaporated to dryness in vacuo, and dissolved 
in dry THF (46 mL). Triethylamine (474 mg, 4.68 mmol) and 1,1'-carbonyldiimidazol (456 mg, 2.81 mmol) were 
then added, and the mixture was stirred at 28 °C for 1 h under argon. After this time, O-(4-methoxybenzyl) 
hydroxylamine (430 mg, 2.81 mmol) was added, and the resulting mixture was stirred for 18 h at 28 °C and 7 h 
at 55 °C under argon. The solvent was removed under reduced pressure, and the residue was partitioned 
between ethyl acetate (100 mL) and brine (50 mL). The aqueous layer was extracted once more with ethyl 
acetate (50 mL), and the combined organic extracts were washed once with brine (50 mL), dried (Na2SO4) and 
evaporated in vacuo. The resulting yellow thick oil was purified by column chromatography eluting with AcOEt-
n-hexane 1:1 to 4:1 to afford the N-(4-methoxybenzyloxy) precursor 41 as a yellowish foamy solid, which 
strongly binds the elution solvents. Removal of the entrapped solvents as in 37 gave 41 as a glass solid (500 mg, 
48% yield over two steps). This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers 
(not assigned). 1H NMR (400 MHz, CDCl3) δ 1.64 (s, 3H, CH3), 2.25-2.75 (br s, 1H, 4-H), 3.28-3.47 (m, 1H, 5-H), 
3.72 (d, 1H, J=18.8 Hz, 5-H), 3.80 (s, 3H, OCH3), 4.27-4.47 (q, AB, 0.9H, JAB≃15.0 Hz, CH2CONHOCH2C6H4OCH3-4), 
4.66 (s, 1.1H, CH2CONHOCH2C6H4OCH3-4), 4.82, 4.84 (s + s, 2H, CONHOCH2C6H4OCH3-4), 6.89 (s, 2H, 3,5-H for 4-
CH3OC6H4), 7.32 (d, 2H, J=8.5 Hz, 2,6-H for 4-CH3OC6H4), 7.72 (d, 2H, J=7.4 Hz, 2,6-H for 4-NO2C6H4), 8.21 (d, 2H, 
J=8.8 Hz, 3,5-H for 4-NO2C6H4), 8.44 (s, 0.43H, CONHOCH2C6H4OCH3-4), 9.15 (s, 0.4H, CONHOCH2C6H4OCH3-4); 
13C NMR (50 MHz, CDCl3) δ 29.0 (3-CH3), 39.7 (CH2CONHOCH2C6H4OCH3-4), 46.0 (5-C), 55.5 (OCH3), 62.7 (3-C), 
 
78.2, 79.4 (CONHOCH2C6H4OCH3-4), 114.3, 124.3, 127.3, 131.3, 146.5, 147.9, 160.4 (aromatic C), 164.9, 170.1 
(CONHOCH2C6H4OCH3-4), 171.0, 173.0 (2,6-C); ESI+ MS: m/z 443.6 [M+H]+. 
A solution of compound 41 (500 mg, 1.13 mmol) and trifluoroacetic acid (8.3 mL) in CH2Cl2 (32 mL) was stirred 
for 10 min, and subsequently treated dropwise with Et3SiH (830 μL) via syringe. After 45 min of stirring at room 
temperature, the color changed from ruby to pale yellow, and the mixture was evaporated to dryness under 
reduced pressure. A slurry of sodium chloride in water (3 mL) was added to the residue, and the mixture was 
treated slowly with solid Na2CO3 to pH 8-9. This thick mixture was then washed five times with ethyl acetate (15 
mL) under vigorous stirring, and the combined washings were dried (Na2SO4) and concentrated to dryness in 
vacuo. The resulting oily residue was chromatographed on silica gel column with AcOEt, as eluent, to afford the 
free base 10 as a yellowish foamy solid (HRMS (ESI): [M+H]+ calcd for C13H14N4O6, 323.0992, found 323.0994). 
This free base material was dissolved in AcOEt-Et2O 1:1 and treated with saturated solution of HCl in Et2O under 
ice cooling. The resulting precipitate was collected by vacuum filtration, triturated with Et2O, and dried in vacuo 
to give 256 mg (63%) of the title compound 10 as an off-white hygroscopic solid (decomposed gradually above 
160 °C); 1H NMR (400 MHz, DMSO-d6) δ 1.62 (s, 3H, CH3), 3.28 (d, 1H, J=18.4 Hz, 5-H), 3.76 (d, 1H, J=18.4 Hz, 5-
H), 4.27 (s, 1.5H, CH2CONHOH, E-isomer), 4.55 (s, 0.5H, CH2CONHOH, Z-isomer), 4.19-5.30 (v br s, NH2+, 
CONHOH, under DMSO water peak),  7.82 (d, 2H, J=8.4 Hz, 2,6-aromatic H), 8.24 (d, 2H, J=8.8 Hz, 3,5-aromatic 
H), 10.31 (s, 0.2H, CONHOH, Z-isomer), 10.78 (s, 0.6H, CONHOH, E-isomer); 13C NMR (50 MHz, DMSO-d6) δ 25.9 
(CH3), 39.8 (CH2CONHOH), 44.1 (5-C), 62.6 (3-C), 123.9, 128.4, 144.6, 147.6 (aromatic C), 163.4 (CONHOH, E-
isomer), 168.7 (CONHOH, Z-isomer), 168.0, 170.6 (2,6-C). Anal. Calcd for C13H15ClN4O6: C, 43.52; H, 4.21; N, 
15.62; Found: C, 43.08; H, 4.46; N, 15.91. 
4.1.48. N-Hydroxy-3,4-dimethyl-2,6-dioxo-3-phenyl-1-piperazineacetamide 11 
The N-benzyloxy precursor 61 was prepared from carboxylic acid 57 (680 mg, 2.46 mmol) following the 
procedure described for the preparation of compound 37 (precursor for 6). The crude oil was purified by flash 
column chromatography eluting with AcOEt-n-hexane 1:1 to afford 61 as a clear glass oil (700 mg, 75%). This 
compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR (600 
MHz, CDCl3, 283 K) δ 1.65 (s , 3H, 3-CH3), 2.57, 2.58 (s + s, 3H, 4-CH3), 3.36-3.44 (dd, 1H, J=8.4, 20.4 Hz, 5-H), 3.65 
(t, 1H, J=15.6, 16.8 Hz, 5-H), 4.30-4.43 (q, AB, 0.96H, JAB=15.0 Hz, CH2CONHOCH2Ph), 4.75 (d, 1.1H, J=4.2 Hz, 
CH2CONHOCH2Ph), 4.89, 4.92 (s + s, 2H, CONHOCH2Ph), 7.27-7.50 (complex m, 10H, aromatic H), 8.52 (s, 0.45H, 
CONHOCH2Ph), 9.0 (s, 0.44H, CONHOCH2Ph); 13C NMR (150 MHz, CDCl3, 283 K) δ 24.2 (3-CH3), 38.1 (4-CH3), 39.1, 
39.5 (CH2CONHOCH2Ph), 54.9 (5-C), 67.8 (3-C), 78.1, 79.5 (CONHOCH2Ph), 125.9, 126.0, 128.0, 128.1, 128.4, 
128.5, 128.6, 128.8, 129.1, 129.3, 134.0, 135.1, 140.5 (aromatic C), 165.0, 170.2 (CONHOCH2Ph), 170.5, 173.7 
(2,6-C); HRMS (ESI): [M+H]+ calcd for C21H23N3O4, 382.1767, found 382.1753. 
Compound 61 (720 mg, 1.89 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 86 mg) in abs EtOH 
(85 mL) as described for the preparation of compound 6 from 37. The crude hydrogenation product (off-white 
foamy solid) was chromatographed over flash silica eluting with AcOEt to afford the title compound 11 as a 
white foamy solid, which strongly binds the aforementioned solvent. Removal of the entrapped solvent as in 6 
gave 11 as a slightly off-yellow solid (495 mg, 90%): mp 158-160 °C (dec); 1H NMR (400 MHz, DMSO-d6) δ 1.56 
(s, 3H, 3-CH3), 2.39, 2.41 (s + s, 3H, 4-CH3), 3.31-3.59 (q, AB, 2H, JAB=17.9 Hz, 5-H), 4.29 (t like, 1.47H, J=16.0 Hz, 
CH2CONHOH, E-isomer), 4.59 (s, 0.46H, CH2CONHOH, Z-isomer), 7.28-7.50 (complex m, 5H, aromatic H), 8.95 (s, 
0.7H, CONHOH, E-isomer), 9.38 (s, 0.2H, CONHOH, Z-isomer), 10.27 (s, 0.2H, CONHOH, Z-isomer), 10.73 (s, 0.7H, 
CONHOH, E-isomer); 13C NMR (100 MHz, DMSO-d6) δ 22.4, 22.5 (3-CH3), 37.3 (4-CH3), 38.8 (CH2CONHOH, E-
isomer), 39.7 (CH2CONHOH, Z-isomer), 54.0 (5-C), 67.3 (3-C), 126.5, 127.9, 128.5 (2,3,4,5,6-aromatic C), 140.7 
(1-aromatic C), 163.8 (CONHOH, E-isomer), 169.2 (CONHOH, Z-isomer), 169.8, 169.9, 173.5 (2,6-C); HRMS (ESI): 
[M+H]+ calcd for C14H17N3O4, 292.1297, found 292.1295. The hydrochloride salt (11·HCl) was prepared as 
described for 6·HCl. Mp 153-156 °C (dec) (slightly hygroscopic). Anal. Calcd for C14H18ClN3O4: C, 51.30; H, 5.54; 
N, 12.82; Found: C, 50.94; H, 5.92; N, 12.51. 
 
4.1.49. N-Hydroxy-4-methyl-2,6-dioxo-3-phenyl-3-propyl-1-piperazineacetamide 12 
The N-benzyloxy precursor 62 was prepared from carboxylic acid 58 (840 mg, 2.76 mmol) following the 
procedure described for the preparation of compound 37 (precursor for 6). The crude viscous oil was purified 
by column chromatography on silica gel with AcOEt-n-hexane 2:3, as eluent, to afford 62 as a glass solid (790 
mg, 69%). This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 
1H NMR (400 MHz, CDCl3) δ 0.73 (t, 3H, J=7.1 Hz, CH3(CH2)2), 1.02-1.20 (m, 2H, CH3CH2CH2), 1.76-2.10 (dm, 2H, 
CH3CH2CH2), 2.44 (s, 3H, 4-CH3), 3.23-3.70 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.12-4.37 (~br s, 1H, CH2CONHOCH2Ph), 
4.55, 4.61 (s + s, 0.9H, CH2CONHOCH2Ph), 4.78 (s, 2H, CONHOCH2Ph), 7.08-7.40 (complex m, 10H, aromatic H), 
8.67-8.86 (br s, 0.32H, CONHOCH2Ph), 9.24-9.45 (br s, 0.41H, CONHOCH2Ph); 13C NMR (50 MHz, CDCl3) δ 14.2 
(CH3(CH2)2), 16.2 (CH3CH2CH2), 37.7 (4-CH3), 38.8 (CH3CH2CH2), 39.4 (CH2CONHOCH2Ph), 55.0 (5-C), 70.3 (3-C), 
78.2, 79.5 (CONHOCH2Ph), 127.0, 128.0, 128.5, 129.2, 134.4, 135.3, 136.9 (aromatic C), 165.2, 170.5, 173.7 
(CONHOCH2Ph, 2,6-C); EI MS: m/z 410.3 ([M+H]+, 2), 409.2 ([M]+, 9), 367.2 ([M+H-CH2CH2CH3]+, 21), 366.2 ([M-
CH2CH2CH3]+, 100), 338.2 (22), 231.2 (79), 174.1 (93), 91.0 (16).   
Compound 62 (1.33 g, 3.25 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 160 mg) in abs EtOH 
(146 mL) as described for the preparation of compound 6 from 37. The crude hydrogenation product (off-white 
foamy solid) was chromatographed on silica gel column with AcOEt, as eluent, to afford the title compound 12 
as a white foamy solid, which strongly binds the elution solvent. Removal of the entrapped solvent as in 6 gave 
12 as a glass solid (903 mg, 87%): 1H NMR (400 MHz, DMSO-d6) δ 0.81 (t, 3H, J=7.2 Hz, CH3(CH2)2), 1.0-1.32 (dm, 
2H, CH3CH2CH2), 1.87 (t, 1H, J=10.8, 11.8 Hz, CH3CH2CHH), 2.07-2.23 (td, 1H, J=2.0, 4.2, 12.6, 13.6 Hz, 
CH3CH2CHH), 2.37, 2.38 (s + s, 3H, 4-CH3), 3.26-3.57 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.29 (s, 1.3H, CH2CONHOH, E-
isomer), 4.58 (s, 0.5H, CH2CONHOH, Z-isomer), 7.27-7.47 (m, 5H, aromatic H), 8.97 (s, 0.6H, CONHOH, E-isomer), 
9.40 (s, 0.2H, CONHOH, Z-isomer), 10.27 (s, 0.2H, CONHOH, Z-isomer), 10.74 (s, 0.6H, CONHOH, E-isomer); 13C 
NMR (50 MHz, DMSO-d6) δ 14.1 (CH3(CH2)2), 16.4 (CH3CH2CH2), 36.9 (4-CH3), 37.7 (CH3CH2CH2), 39.0 
(CH2CONHOH, E-isomer), 39.8 (CH2CONHOH, Z-isomer), 53.9 (5-C), 70.0 (3-C), 127.2, 127.9, 128.3 (2,3,4,5,6-
aromatic C), 136.2 (1-aromatic C), 163.8 (CONHOH, E-isomer), 169.2 (CONHOH, Z-isomer), 169.7, 173.3 (2,6-C); 
HRMS (ESI): [M+H]+ calcd for C16H21N3O4, 320.1610, found 320.1617. The hydrochloride salt (12·HCl) was 
prepared by treating a diethyl ether solution of 12 with saturated solution of HCl in Et2O under ice cooling. The 
resulting white solid was collected by vacuum filtration, triturated with Et2O, and dried in vacuo (decomposed 
gradually above 110 °C). Anal. Calcd for C16H22ClN3O4: C, 54.01; H, 6.23; N, 11.81; Found: C, 53.65; H, 5.96; N, 
11.62. 
4.1.50. 3-Butyl-N-hydroxy-4-methyl-2,6-dioxo-3-phenyl-1-piperazineacetamide 13 
The N-benzyloxy precursor 63 was prepared from carboxylic acid 59 (1.2 g, 3.77 mmol) following the procedure 
described for the preparation of compound 37 (precursor for 6). The crude yellowish oil was purified by flash 
column chromatography eluting with AcOEt-n-hexane 2:3 to afford 63 as a white foamy solid, which strongly 
binds the elution solvents. Removal of the entrapped solvents as in 37 gave 63 as a glass solid (1 g, 63%). This 
compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR (600 
MHz, CDCl3) δ 0.74 (t, 3H, J=7.1 Hz, CH3(CH2)3), 1.03-1.21 (m, 4H, CH3CH2CH2CH2), 1.84-2.10 (dm, 2H, 
CH3(CH2)2CH2), 2.46 (s, 3H, 4-CH3), 3.26-3.68 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.18-4.38 (br d, 1H, J=24.0 Hz, 
CH2CONHOCH2Ph), 4.53-4.69 (br s, 1H, CH2CONHOCH2Ph), 4.81 (s, 2H, CONHOCH2Ph), 7.14-7.38 (complex m, 
10H, aromatic H), 8.40-8.65 (br s, 0.6H, CONHOCH2Ph), 8.85-9.10 (br s, 0.6H, CONHOCH2Ph); 13C NMR (50 MHz, 
CDCl3) δ 14.0 (CH3(CH2)3), 22.9 (CH3CH2(CH2)2), 24.9 (CH3CH2CH2CH2), 36.4 (CH3(CH2)2CH2), 37.8 (4-CH3),  39.5 
(CH2CONHOCH2Ph), 55.1 (5-C), 70.3 (3-C), 78.3, 79.5 (CONHOCH2Ph), 127.1, 128.1, 128.6, 129.3, 134.4, 135.3, 
136.8 (aromatic C), 165.2, 170.6, 173.8 (CONHOCH2Ph, 2,6-C); ESI+ MS: m/z 424.4 [M+H]+. 
Compound 63 (900 mg, 2.13 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 108 mg) in abs EtOH 
(96 mL) as described for the preparation of 6 from 37. The crude hydrogenation product (off-white foamy solid) 
was chromatographed on silica gel column with AcOEt, as eluent, to afford the title compound 13 as a white 
 
foamy solid, which strongly binds the elution solvent. Removal of the entrapped solvent as in 6 gave 13 as a 
glass solid (665 mg, 94%): 1H NMR (600 MHz, DMSO-d6) δ 0.81 (t, 3H, J=7.1 Hz, CH3(CH2)3), 0.99-1.13 (m, 1H, 
CH3CH2CHHCH2), 1.15-1.30 (m, 3H, CH3CH2CHHCH2), 1.84-1.96 (m, 1H, CH3(CH2)2CHH), 2.12-2.24 (m, 1H, 
CH3(CH2)2CHH), 2.37, 2.38 (s + s, 3H, 4-CH3), 3.29-3.56 (q, AB, 2H, JAB=18.0 Hz, 5-H), 4.27 (s, 1.45H, CH2CONHOH, 
E-isomer), 4.57 (s, 0.5H, CH2CONHOH, Z-isomer), 7.30-7.45 (m, 5H, aromatic H), 8.92 (s, 0.6H, CONHOH, E-
isomer), 9.34 (s, 0.2H, CONHOH, Z-isomer), 10.24 (s, 0.2H, CONHOH, Z-isomer), 10.70 (s, 0.6H, CONHOH, E-
isomer); 13C NMR (50 MHz, DMSO-d6) δ 13.9 (CH3(CH2)3), 22.4 (CH3CH2(CH2)2), 25.2 (CH3CH2CH2CH2), 35.2 
(CH3(CH2)2CH2), 36.8 (4-CH3), 39.0 (CH2CONHOH, E-isomer), 39.8 (CH2CONHOH, Z-isomer), 53.9 (5-C), 69.9 (3-C), 
127.3, 128.0, 128.3 (2,3,4,5,6-aromatic C), 136.2 (1-aromatic C), 163.8 (CONHOH, E-isomer), 169.2 (CONHOH, Z-
isomer), 169.7, 173.3 (2,6-C); HRMS (ESI): [M+H]+ calcd for C17H23N3O4, 334.1767, found 334.1761. The 
hydrochloride salt (13·HCl) was prepared as described for 12·HCl. Mp 162-166 °C (dec). Anal. Calcd for 
C17H24ClN3O4: C, 55.21; H, 6.54; N, 11.36; Found: C, 55.52; H, 6.23; N, 11.56. 
4.1.51. 3-(4-Fluorophenyl)-N-hydroxy-3,4-dimethyl-2,6-dioxo-1-piperazineacetamide 14 
The N-benzyloxy precursor 64 was prepared from carboxylic acid 60 (1 g, 3.4 mmol) in dry THF-DMF 4:1 following 
the procedure described for the preparation of compound 40 (precursor for 9). The crude oil was purified by 
column chromatography on silica gel eluting with AcOEt-n-hexane 1:2 and then 1:1 to afford 64 as a clear glass 
oil (1.03 g, 76%). This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not 
assigned). 1H NMR (400 MHz, CDCl3) δ 1.63 (s, 3H, 3-CH3), 2.53 (s, 3H, 4-CH3), 3.37-3.66 (q, AB, 2H, JAB=18.0 Hz, 
5-H), 4.26-4.50 (br d, 0.9H, J=21.2 Hz, CH2CONHOCH2Ph), 4.69-4.79 (br s, 1H, CH2CONHOCH2Ph), 4.91 (s, 2H, 
CONHOCH2Ph), 7.04 (t, 2H, J≃8.7 Hz, 3,5-H for 4-FC6H4), 7.29-7.50 (complex m, 7H, C6H5, 2,6-H for 4-FC6H4), 8.31 
(br s, 0.4H, CONHOCH2Ph), 8.73 (br s, 0.4H, CONHOCH2Ph); 13C NMR (150 MHz, CDCl3) δ 23.9 (3-CH3), 38.2 (4-
CH3), 39.6 (CH2CONHOCH2Ph), 54.9 (5-C), 67.5 (3-C), 78.4, 79.7 (CONHOCH2Ph), 115.7, 115.9 (d, JC-F=21.2 Hz, 3,5-
C for 4-FC6H4), 128.1, 128.2 (d, JC-F=7.5 Hz, 2,6-C for 4-FC6H4), 128.5, 128.6, 128.8, 129.3, 129.4 (2,3,4,5,6-C for 
C6H5), 134.3, 135.2 (1-C for C6H5), 136.6 (1-C for 4-FC6H4), 161.7, 163.3 (d, JC-F=246 Hz, 4-C for 4-FC6H4), 165.2 
(weak signal intensity), 170.3, 173.7 (CONHOCH2Ph, 2,6-C); ESI+ MS: m/z 400.2 [M+H]+.  
Compound 64 (1 g, 2.5 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 120 mg) in abs EtOH (112 
mL) as described for the preparation of 6 from 37. The crude hydrogenation product (off-white foamy solid) was 
chromatographed on silica gel column with AcOEt, as eluent, to afford the title compound 14 as a white foamy 
solid, which strongly binds the elution solvent. Removal of the entrapped solvent as in 6 gave 14 as a glass solid 
(703 mg, 91%): 1H NMR (400 MHz, DMSO-d6) δ 1.56 (s, 3H, 3-CH3), 2.35, 2.37 (s + s, 3H, 4-CH3), 3.33-3.60 (q, AB, 
2H, JAB≃18.0 Hz, 5-H), 4.27 (s, 1.4H, CH2CONHOH, E-isomer), 4.57 (s, 0.5H, CH2CONHOH, Z-isomer), 7.19 (t, 2H, 
J=8.7 Hz, 3,5-aromatic H), 7.46-7.54 (~q, 2H, J=4.4, 5.4 Hz, 2,6-aromatic H), 8.96 (s, 0.7H, CONHOH, E-isomer), 
9.39 (s, 0.2H, CONHOH, Z-isomer), 10.28 (s, 0.2H, CONHOH, Z-isomer), 10.74 (s, 0.6H, CONHOH, E-isomer); 13C 
NMR (50 MHz, DMSO-d6) δ 21.7, 21.8 (3-CH3), 37.2 (4-CH3), 38.9 (CH2CONHOH, E-isomer), 39.7 (CH2CONHOH, Z-
isomer), 53.8 (5-C), 66.8 (3-C), 115.0, 115.5 (d, JC-F=21.1 Hz, 3,5-aromatic C), 128.7, 128.9 (d, JC-F=7.9 Hz, 2,6-
aromatic C), 136.9, 137.0 (d, JC-F=3.1 Hz, 1-aromatic C), 159.2, 164.0 (d, JC-F=243 Hz, 4-aromatic C), 163.8 
(CONHOH, E-isomer), 169.2 (CONHOH, Z-isomer), 169.6, 173.4 (2,6-C); HRMS (ESI): [M+Na]+ calcd for 
C14H16FN3O4, 332.1023, found 332.1021. The hydrochloride salt (14·HCl) was prepared as described for 12·HCl 
(decomposed gradually above 126 °C). Anal. Calcd for C14H17ClFN3O4: C, 48.63; H, 4.96; N, 12.15; Found: C, 48.34; 
H, 5.27; N, 11.94. 
4.1.52. N-Hydroxy-3,4-dimethyl-3-(4-nitrophenyl)-2,6-dioxo-1-piperazineacetamide 15 
The N-(4-methoxybenzyloxy) precursor 65 was prepared from 4-methoxybenzyl ester 56 (1 g, 2.27 mmol) by the 
same method as for 41 (precursor for 10). The crude oil was purified by column chromatography on silica gel 
with AcOEt-n-hexane 1:1, as eluent, to afford 65 as a yellowish thick oil (445 mg, 43% yield over two steps). This 
compound appears in the 1H NMR spectrum as two pairs of rotamers for the E/Z isomers as deduced both from 
the number of signals ad their integration. 1H NMR (400 MHz, CDCl3) δ [1.60 (s), 1.66 (s)] 3H, 3-CH3, [2.21 (s), 
 
2.54 (s)] 3H, 4-CH3, [2.82-3.03 (q, J=13.4, 16.3 Hz), 3.43-3.62 (q, AB, JAB=18.1 Hz)] 2H, 5-H, [3.77 (s), 3.80 (s)] 
OCH3, 4.26-4.47 (q, J=14.0, 16.7 Hz, CH2CONHOCH2C6H4OCH3-4), 4.60 (s, CONHOCH2C6H4OCH3-4), [4.69 (s), 4.71 
(s)] CH2CONHOCH2C6H4OCH3-4, 4.83 (s, CONHOCH2C6H4OCH3-4), [6.83 (d, J=8.3 Hz), 6.89 (d, J=8.1 Hz)] 3,5-H for 
4-CH3OC6H4), [7.23 (d, J=8.1 Hz), 7.26-7.37 (q, J=8.4, 9.0 Hz)] 2,6-H for 4-CH3OC6H4), [7.63 (d, J=7.6 Hz), 7.70 (d, 
J=8.6 Hz)] 2,6-H for 4-NO2C6H4), [8.05-8.17 (m), 8.20 (d, J=8.5 Hz)] 3,5-H for 4-NO2C6H4), [8.61 (br s), 9.09 (br s), 
10.11 (br s), 10.38 (br s)] CONHOCH2C6H4OCH3-4); 13C NMR (50 MHz, CDCl3) δ 23.3 (3-CH3), 37.8 (weak signal 
intensity), 38.2 (4-CH3), 39.6 (CH2CONHOCH2C6H4OCH3-4), 54.7 (5-C), 55.3 (OCH3), 67.8 (3-C), 77.7, 79.4 
(CONHOCH2C6H4OCH3-4), 113.9, 114.1, 123.6, 124.1, 127.6, 128.2, 129.3, 130.2, 131.0, 131.1, 147.2, 147.7, 
148.3 (aromatic C), 159.6, 160.1 (CONHOCH2C6H4OCH3-4), 169.6, 172.7 (2,6-C); ESI+ MS: m/z 457.2 [M+H]+. 
Compound 65 (460 mg, 1.01 mmol) was subjected to treatment with TFA (7.4 mL) and Et3SiH (742 μL) in dry 
CH2Cl2 (28 mL) as described for the preparation of compound 10 from 41. The crude product (yellow foamy 
solid) was chromatographed on silica gel column eluting successively with AcOEt-n-hexane 2:1, AcOEt and 
AcOEt-MeOH 9:1 to afford the title compound 15 as a pale yellow foamy solid, which strongly binds the 
aforementioned solvents. Removal of the entrapped solvents as in 6 gave 15 as a light-yellow solid (237 mg, 
70%): 1H NMR (400 MHz, DMSO-d6) δ 1.61 (s, 3H, 3-CH3), 2.36, 2.39 (s + s, 3H, 4-CH3), 3.41-3.66 (q, AB, 2H, 
JAB=18.0 Hz, 5-H), 4.27 (s, 1.4H, CH2CONHOH, E-isomer), 4.51-4.65 (q, AB, 0.6H, JAB=17.0 Hz, CH2CONHOH, Z-
isomer), 7.76 (d, 2H, J=8.8 Hz, 2,6-aromatic H), 8.22 (d, 2H, J=8.8 Hz, 3,5-aromatic H), 8.96 (s, 0.7H, CONHOH, E-
isomer), 9.40 (s, 0.3H, CONHOH, Z-isomer), 10.30 (s, 0.2H, CONHOH, Z-isomer), 10.74 (s, 0.7H, CONHOH, E-
isomer); 13C NMR (50 MHz, DMSO-d6) δ 20.9 (3-CH3), 37.2 (4-CH3), 38.9 (CH2CONHOH), 53.7 (5-C), 67.2 (3-C), 
123.6 (3,5-aromatic C), 128.2 (2,6-aromatic C), 147.1, 148.6 (1,4-aromatic C), 163.6 (CONHOH, E-isomer), 169.0 
(CONHOH, Z-isomer), 169.3, 172.8 (2,6-C); HRMS (ESI): [M+H]+ calcd for C14H16N4O6, 337.1148, found 337.1157. 
The hydrochloride salt (15·HCl) was prepared by the same way described for 10, and obtained as an off-white 
slightly hygroscopic solid (decomposed gradually above 166 °C). Anal. Calcd for C14H17ClN4O6: C, 45.11; H, 4.60; 
N, 15.03; Found: C, 44.78; H, 4.52; N, 15.28. 
4.1.53. N-Hydroxy-3-methyl-2,6-dioxo-3-phenyl-4-propyl-1-piperazineacetamide Hydrochloride 16 
The N-benzyloxy precursor 74 was prepared from carboxylic acid 72 (496 mg, 1.63 mmol) following the 
procedure described for the preparation of compound 37 (precursor for 6). The crude yellowish thick oil was 
purified by column chromatography on silica gel with AcOEt-n-hexane 2:3, as eluent, to afford 74 as a glass solid 
(433 mg, 65%). This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not 
assigned). 1H NMR (400 MHz, CDCl3) δ 0.92 (t, 3H, J=7.4 Hz, NCH2CH2CH3), 1.40-1.61 (m, 2H, NCH2CH2CH3), 1.66 
(s, 3H, 3-CH3), 2.53-2.64 (br s, 1H, NCHHCH2CH3), 2.66-2.78 (m, 1H, NCHHCH2CH3), 3.45-3.70 (q, AB, 2H, JAB=18.4 
Hz, 5-H), 4.21-4.55 (v br d, 0.9H, CH2CONHOCH2Ph), 4.66-4.82 (br s, 0.9H, CH2CONHOCH2Ph), 4.91 (s, 2H, 
CONHOCH2Ph), 7.22-7.53 (complex m, 10H, aromatic H), 7.99-8.40 (v br s, 0.4H, CONHOCH2Ph), 8.42-8.85 (v br 
s, 0.3H, CONHOCH2Ph); 13C NMR (150 MHz, CDCl3) δ 11.7 (NCH2CH2CH3), 21.4 (NCH2CH2CH3), 23.3 (3-CH3), 39.8 
(CH2CONHOCH2Ph), 50.7 (NCH2CH2CH3), 51.1 (5-C), 68.2 (3-C), 78.4, 79.7 (CONHOCH2Ph), 126.4, 128.3, 128.9, 
129.4, 134.3, 135.3, 141.4 (aromatic C), 165.1, 170.3 (CONHOCH2Ph), 170.7, 174.0 (2,6-C); ESI+ MS: m/z 410.4 
[M+H]+. 
Compound 74 (390 mg, 0.95 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 47 mg), in abs EtOH 
(43 mL) as described for the preparation of 6 from 37. The crude hydrogenation material (off-white foamy solid) 
was chromatographed on silica gel column eluting first with AcOEt-n-hexane 2:1 and then AcOEt to afford the 
free base 16 as a white foamy solid, which strongly binds the elution solvents. (EI MS: m/z 319.1 ([M]+, 13), 291.1 
(14), 276.1 ([M-CH2CH2CH3]+, 11), 231.1 (26), 174.0 (100)). This free base product was converted into the HCl 
salt as described for compound 12 to give 238 mg (70%) of the title compound 16 as a white slightly hygroscopic 
solid (decomposed gradually above 115 °C); 1H NMR (400 MHz, DMSO-d6) δ 0.78 (t, 3H, J=7.2 Hz, +NH(CH2)2CH3), 
1.32-1.59 (complex m, 2H, +NHCH2CH2CH3), 1.73 (s, 3H, 3-CH3), 2.34-2.53 (m, 1H, +NHCHHCH2CH3), 2.62-2.88 (br 
s, 1H, +NHCHHCH2CH3), 3.46-3.93 (q, AB, 2H, JAB≃16.0 Hz, 5-H), 4.28 (s, 1.5H, CH2CONHOH, E-isomer), 4.56 (s, 
 
0.5H, CH2CONHOH, Z-isomer), 6.52-8.41 (br m, 7H, CONHOH, +NH(CH2)2CH3,  aromatic H), 10.29 (s, 0.2H, 
CONHOH, Z-isomer), 10.84 (s, 0.5H, CONHOH, E-isomer); 13C NMR (50 MHz, DMSO-d6) δ 11.3 (+NH(CH2)2CH3), 
19.8 (+NHCH2CH2CH3), 20.6 (3-CH3), 39.5 (CH2CONHOH, E-isomer), 40.4 (CH2CONHOH, Z-isomer), 50.0 (5-C), 50.6 
(+NHCH2CH2CH3), 68.0 (3-C), 127.3, 128.6 (2,3,4,5,6-aromatic C), 139.1 (1-aromatic C), 163.5 (CONHOH, E-
isomer), 168.9 (CONHOH, Z-isomer), 168.4, 172.6 (2,6-C). Anal. Calcd for C16H22ClN3O4: C, 54.01; H, 6.23; N, 
11.81; Found: C, 53.66; H, 6.62; N, 12.14.  
Note. The above prepared free base 16 was partially decomposed on attempted drying at 62-64 °C under high 
vacuum (10-2 mmHg). 
4.1.54. 4-Butyl-N-hydroxy-3-methyl-2,6-dioxo-3-phenyl-1-piperazineacetamide Hydrochloride 17 
The N-benzyloxy precursor 75 was prepared from carboxylic acid 73 (465 mg, 1.46 mmol) following the 
procedure described for the preparation of compound 37 (precursor for 6). The crude yellowish thick oil was 
purified by column chromatography on silica gel with AcOEt-n-hexane 1:2, as eluent, to afford 75 as a glass oil, 
which solidified under cooling (white solid, 400 mg, 65% yield): mp 128-129 °C (AcOEt/Et2O 1:10-n-pentane). 
This compound appears in the 1H and 13C NMR spectra as a mixture of E/Z conformers (not assigned). 1H NMR 
(400 MHz, CDCl3) δ 0.90 (t, 3H, J=7.3 Hz, N(CH2)3CH3), 1.24-1.55 (complex m, 4H, NCH2CH2CH2CH3), 1.49 (s, 3H, 
3-CH3), 2.50-2.67 (br s, 1H, NCHH(CH2)2CH3), 2.69-2.82 (m, 1H, NCHH(CH2)2CH3), 3.49-3.65 (q, AB, 2H, JAB=18.2 
Hz, 5-H), 4.15-4.53 (v br d, 0.8H, CH2CONHOCH2Ph), 4.72 (s, 0.9H, CH2CONHOCH2Ph), 4.89 (s, 2H, CONHOCH2Ph), 
7.20-7.53 (complex m, 10H, aromatic H), 8.30-8.47 (br s, 0.4H, CONHOCH2Ph), 8.67-8.91 (br s, 0.4H, 
CONHOCH2Ph); 13C NMR (150 MHz, CDCl3) δ 14.0 (N(CH2)3CH3), 20.2 (N(CH2)2CH2CH3), 23.2 (3-CH3), 30.4 
(NCH2CH2CH2CH3), 39.7 (CH2CONHOCH2Ph), 48.4 (NCH2(CH2)2CH3), 51.0 (5-C), 68.1 (3-C), 78.3, 79.7 
(CONHOCH2Ph), 126.3, 128.1, 128.9, 129.4, 134.4, 135.3, 141.5 (aromatic C), 165.2, 170.3 (CONHOCH2Ph) 170.9, 
174.1 (2,6-C). Anal. Calcd for C24H29N3O4: C, 68.06; H, 6.90; N, 9.92; Found: C, 68.32; H, 7.02; N, 9.63.  
Compound 75 (620 mg, 1.46 mmol) was subjected to catalytic hydrogenation (H2/10% Pd-C, 74 mg) in abs EtOH 
(66 mL) as described for the preparation of 6 from 37. The crude hydrogenation material (off-white foamy solid) 
was chromatographed on silica gel column with AcOEt-n-hexane 1:1, as eluent, to afford the free base 17 as a 
white foamy solid, which strongly binds the elution solvents. (CI+ MS: m/z 334.1 ([M+H]+, 7), 333.1 ([M]+, 6), 
305.1 (17), 276.0 ([M-CH2CH2CH2CH3]+, 10), 245.1 (35), 188.1 (100)). This free base product was converted into 
the HCl salt as described for compound 12 to give 369 mg (68%) of the title compound 17 as a white slightly 
hygroscopic solid (decomposed gradually above 108 °C); 1H NMR (400 MHz, DMSO-d6) δ 0.67 (t, 3H, J=7.4 Hz, 
+NH(CH2)3CH3), 1.0-1.20 (complex m, 2H, +NH(CH2)2CH2CH3), 1.22-1.36 (complex m, 2H, +NHCH2CH2CH2CH3), 1.54 
(s, 3H, 3-CH3), 2.31-2.44 (m, 2H, +NHCH2(CH2)2CH3), 3.30-3.68 (q, AB, 2H, JAB=17.4 Hz, 5-H), 4.14 (s, 1.5H, 
CH2CONHOH, E-isomer), 4.43 (s, 0.5H, CH2CONHOH, Z-isomer), 5.40-6.80 (v br s, 2H, CONHOH, +NH(CH2)3CH3), 
7.15-7.48 (m, 5H, aromatic H), 10.14 (s, 0.2H, CONHOH, Z-isomer), 10.66 (s, 0.5H, CONHOH, E-isomer); 13C NMR 
(50 MHz, DMSO-d6) δ 13.6 (+NH(CH2)3CH3), 19.5 (+NH(CH2)2CH2CH3), 20.7 (3-CH3), 29.0 (+NHCH2CH2CH2CH3), 39.1 
(CH2CONHOH, E-isomer), 39.9 (CH2CONHOH, Z-isomer), 48.0 (+NHCH2(CH2)2CH3), 50.1 (5-C), 67.7 (3-C), 126.9, 
128.1, 128.4 (2,3,4,5,6-aromatic C), 140.4 (1-aromatic C), 163.6 (CONHOH, E-isomer), 169.0 (CONHOH, Z-
isomer), 169.1, 173.2 (2,6-C). Anal. Calcd for C17H24ClN3O4: C, 55.20; H, 6.54; N, 11.36; Found: C, 54.83; H, 6.86; 
N, 11.02. 
Note. The above prepared free base 17 was partially decomposed on attempted drying at 62-64 °C under high 
vacuum (10-2 mmHg). 
4.2 Biological Assays 
4.2.1. Trypanocidal assays 
Bloodstream form T. brucei (strain 221) were cultured in modified Iscove’s medium, as outlined previously [11]. 
Eight-point potency curves were performed in 96 well plates (200 L volumes), and the compound 
concentrations that inhibited growth by 50% (IC50) and 90% (IC90) were determined. Parasites were first diluted 
to 2.5 × 104 mL−1, compounds were added at range of concentrations, and the plates incubated at 37 °C. 
 
Resazurin was added after 48 h, and the plates incubated for a further 16 h. Fluorescence intensities were 
determined using a BMG FLUOstar Omega (excitation 545 nm, emission 590 nm). Data were analysed using 
Graph Pad Prism 7 software. Values are expressed as IC50 ± SD and are the average of three independent 
replicates. 
4.2.2 In vitro cytotoxicity assays on rat skeletal myoblast L6 cells 
Cytotoxicity against L6 cells was assessed using microtitre plates. Briefly, cells  were seeded in triplicate at 1 × 
104 mL−1 in growth medium containing different compound concentrations. The plates were incubated for 6 
days at 37 °C and resazurin then added to each well. After a further 8 h incubation, the fluorescence was 
determined using a Spectramax plate reader. 
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